

(19) World Intellectual Property
Organization
International Bureau



(43) International Publication Date
15 April 2004 (15.04.2004)

PCT

(10) International Publication Number
WO 2004/031376 A2

- (51) International Patent Classification⁷: C12N 9/00 (74) Common Representative: FIRMENICH SA; 1, route des Jeunes, P.O. Box 239, CH-1211 Geneva 8 (CH).
- (21) International Application Number: PCT/IB2003/005072 (81) Designated States (*national*): AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW.
- (22) International Filing Date: 2 October 2003 (02.10.2003)
- (25) Filing Language: English
- (26) Publication Language: English
- (30) Priority Data:
60/415,765 4 October 2002 (04.10.2002) US
PCT/IB02/05070 2 December 2002 (02.12.2002) IB
- (71) Applicant (*for all designated States except US*): FIRMENICH SA [CH/CH]; 1, route des Jeunes, P.O. Box 239, CH-1211 Geneva 8 (CH).
- (72) Inventors; and
- (75) Inventors/Applicants (*for US only*): SCHALK, Michel [FR/FR]; Collonges des Jeunes 1 (FR). CLARK, Anthony [GB/FR]; 125 chemin du Moulin de Naz, Esserts Saleve, F-75460 Monnetier Mornex (FR).
- (84) Designated States (*regional*): ARIPO patent (GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG).
- Published:**
— *without international search report and to be republished upon receipt of that report*
- For two-letter codes and other abbreviations, refer to the "Guidance Notes on Codes and Abbreviations" appearing at the beginning of each regular issue of the PCT Gazette.*

(54) Title: SESQUITERPENE SYNTHASES AND METHODS OF USE

(57) Abstract: The invention relates to sesquiterpene synthases and methods of their production and use. In one embodiment, the invention provides nucleic acids comprising a nucleotide sequence as described herein that encodes for at least one sesquiterpene synthases. In a further embodiment, the invention also provides for sesquiterpene synthases and methods of making and using these enzymes. For example, sesquiterpene synthases of the invention may be used to convert farnesyl-pyrophosphate to various oxygenated and aliphatic sesquiterpenes including valencene, bicyclo-germacrene, cubebol and delta-cadinene.

WO 2004/031376 A2

Sesquiterpene Synthases and Methods of Use

[0001] This application claims the benefit of U.S. Provisional Application No. 60/415,765, filed October 4, 2002, and the contents of which are incorporated by reference herein. This application also claims the benefit of priority of International Application, PCT/IB02/05070, filed December 2, 2002, the contents of which are incorporated by reference herein.

[0002] The present invention relates to sesquiterpene synthases and methods of their production and use. In one embodiment, the invention provides nucleic acids comprising a nucleotide sequence as described herein that encodes for at least one sesquiterpene synthase. In a further embodiment, the invention also provides for sesquiterpene synthases and methods of making and using these enzymes. For example, sesquiterpene synthases of the invention may be used to convert farnesyl-pyrophosphate to various oxygenated and aliphatic sesquiterpenes including valencene, bicyclo-germacrene, cubebol and delta-cadinene.

Background of the Invention

[0003] Terpene compounds represent a wide range of natural molecules with a large diversity of structure. The plant kingdom contains the highest diversity of monoterpenes and sesquiterpenes. Often they play a role in defense of the plants against pathogens, insects and herbivores and for attraction of pollinating insect.

[0004] The biosynthesis of terpenes has been extensively studied in many organisms. The common precursor to terpenes is isopentenyl pyrophosphate (IPP) and many of the enzymes catalyzing the steps leading to IPP have been characterized. Two distinct pathways for IPP biosynthesis are currently known (Figure 1). The mevalonate pathway is found in the plants cytosol and in yeast and the non-mevalonate pathway (or deoxyxylulose-5-phosphate (DXP) pathway is found in the plant plastids and in *E. coli*.

[0005] For example, the IPP is isomerized to dimethylallyl diphosphate by the IPP isomerase and these two C5 compounds can be condensed by prenyl transferases to form the acyclic pyrophosphate terpene precursors for each class of terpenes, i.e. geranyl-pyrophosphate (GPP) for the monoterpenes, farnesyl-pyrophosphate (FPP) for the sesquiterpenes, geranylgeranyl-pyrophosphate (GGPP) for the diterpenes (Figure 2). The enzymes catalyzing the cyclisation step of the acyclic precursors are named terpene cyclases or terpene synthases, which are referred to as terpene synthases herein.

[0006] These enzymes may be able to catalyze complex multiple step cyclization to form the carbon skeleton of a terpene or sesquiterpene compound. For example, the initial step of the catalyzed cyclisation may be the ionization of the diphosphate group to form a allylic cation. The substrate then undergoes isomerizations and rearrangements which can be controlled by the enzyme active site. The product may, for example, be acyclic, mono-, di or tri-cyclic. A proton may then be released from the carbocation or the carbocation reacts with a water molecule and the terpene hydrocarbon or alcohol is released. Some terpene synthases produce a single product, but many produce multiple products.

[0007] A large diversity of terpene structures and sesquiterpene synthases are found in nature. Several sesquiterpene synthase encoding cDNA or genes have been cloned and characterized from different plant sources, e.g, 5-epi-aristolochene synthases from *Nicotiana tabacum* (Facchini, P.J. and Chappell, J. (1992) *Proc. Natl. Acad. Sci. U.S.A.* 89, 11088-11092.) and from *Capsicum annum* (Back, K., et al. (1998) *Plant Cell Physiol.* 39 (9), 899-904.), a vetispiradiene synthase from *Hyoscyamus muticus* (Back, K. and Chappell, J. (1995) *J. Biol. Chem.* 270 (13), 7375-7381.), a (E)- β -farnesene synthase from *Mentha piperita* (Crock, J., et al. (1997) *Proc. Natl. Acad. Sci. U.S.A.* 94 (24), 12833-12838.), a δ -selinene synthase and a γ -humulene synthase from *Abies grandis* (Steele, C.L., et al. (1998) *J. Biol. Chem.* 273 (4), 2078-2089.), δ -cadinene synthases from *Gossypium arboreum* (Chen, X.Y., et al. (1995) *Arch. Biochem. Biophys.* 324

(2), 255-266; Chen, X.Y., et al. (1996) J. Nat Prod. 59, 944-951.), a E- α -bisabolene synthase from *Abies grandis* (Bohlmann, J., et al. (1998) Proc. Natl. Acad. Sci. U.S.A. 95 (12), 6756-6761.), a germacrene C synthase from *Lycopersicon esculentum* (Colby, S.M., et al. (1998) Proc. Natl. Acad. Sci. U.S.A. 95 (5), 2216-2221.), an epi-cedrol synthase and an amorpho-4,11-diene synthase from *Artemisia annua* (Mercke, P., et al. (1999) Arch. Biochem. Biophys. 369 (2), 213-222; Mercke, P., et al. (2000) Arch. Biochem. Biophys. 381 (2), 173-180.), and germacrene A synthases from *Lactuca sativa*, from *Cichorium intybus* and from *Solidago canadensis* (Bennett, M.H., et al. (2002) Phytochem. 60, 255-261; Bouwmeester, H.J., et al. (2002) Plant Physiol. 129 (1), 134-144; Prosser I, et al. (2002) Phytochem. 60, 691-702).

[0008] Many sesquiterpene compounds are used in perfumery (e.g. patchoulol, nootkatone, santalol, vetivone, sinensal) and many are extracted from plants. As a result, their availability and prices may be subject to fluctuation related to the availability of the plants and the stability of the producing countries. The availability of a plant-independent system for production of sesquiterpenes may therefore be of interest. Due to the structural complexity of some sesquiterpenes, their chemical synthesis at an acceptable cost may not always be feasible.

Summary of the Invention

[0009] In one embodiment, the invention relates to isolated nucleic acids that encode sesquiterpene synthases. As used herein, a sesquiterpene synthase may also be referred to by at least one compound produced by the enzyme upon contact with an acyclic pyrophosphate terpene precursor such as farnesyl-pyrophosphate. For example, a sesquiterpene synthase capable of producing bicylogermacrene as one of its products may be referred to as bicylogermacrene synthase. Using this convention, examples of nucleic acids of the invention include cDNAs encoding cubebol synthase (GFTpsC) (SEQ ID NO:1); δ -cadine synthase (GFTpsE) (SEQ ID NO:2); bicylogermacrene

synthase (GFTpsB) (SEQ ID NO:3); valencene synthase (GFTpsD1 & GFTpsD2) (SEQ ID NO:4 & SEQ ID NO:5); and.

[0010] In one embodiment, the invention provides an isolated nucleic acid selected from: (a) a nucleic acid comprising the nucleotide sequence substantially as set out in SEQ ID NO:6, SEQ ID NO:7, SEQ ID NO:8, SEQ ID NO:9, or SEQ ID NO:10; (b) a nucleic acid encoding the polypeptide substantially set out in SEQ ID NO:1, SEQ ID NO:2, SEQ ID NO:3, SEQ ID NO:4, or SEQ ID NO:5; and (c) a nucleic acid that hybridizes to the nucleic acid of (a) or (b) under low stringency conditions, wherein the polypeptide encoded by said nucleic acid is a sesquiterpene synthase. In one embodiment, the defined conditions are moderate stringency conditions and in a further embodiment high stringency conditions. Other embodiments include: a polypeptide encoded by a nucleic acid of the invention; a host cell comprising a nucleic acid of the invention; a non-human organism modified to harbor a nucleic acid of the invention; and methods of producing a polypeptide comprising culturing host cells of the invention.

[0011] In another embodiment, the invention provides an isolated polypeptide comprising an amino acid sequence substantially as set out in SEQ ID NO:1, SEQ ID NO:2, SEQ ID NO:3, SEQ ID NO:4, or SEQ ID NO:5.

[0012] In a further embodiment, the invention provides a vector comprising at least one nucleic acid chosen from (a) a nucleic acid comprising the nucleotide sequence substantially as set out in SEQ ID NO:6, SEQ ID NO:7, SEQ ID NO:8, SEQ ID NO:9, or SEQ ID NO:10; (b) a nucleic acid encoding the polypeptide substantially set out in SEQ ID NO:1, SEQ ID NO:2, SEQ ID NO:3, SEQ ID NO:4, or SEQ ID NO:5; and (c) a nucleic acid that hybridizes to the nucleic acid of (a) or (b) under low stringency conditions, wherein the polypeptide encoded by said nucleic acid is a sesquiterpene synthase. Other embodiments include, methods of making a recombinant host cell comprising introducing a vector of the invention into a host cell.

[0013] In one embodiment, the invention provides a method of making at least one sesquiterpene synthase comprising culturing a host modified to contain at least one nucleic acid sequence under conditions conducive to the

production of said at least one sesquiterpene synthase. In one embodiment, the at least one nucleic acid is chosen from (a) a nucleic acid comprising the nucleotide sequence substantially as set out in SEQ ID NO:6, SEQ ID NO:7, SEQ ID NO:8, SEQ ID NO:9, or SEQ ID NO:10; (b) a nucleic acid encoding the polypeptide substantially set out in SEQ ID NO:1, SEQ ID NO:2, SEQ ID NO:3, SEQ ID NO:4, or SEQ ID NO:5; and (c) a nucleic acid that hybridizes to the nucleic acid of (a) or (b) under low stringency conditions, wherein the polypeptide encoded by said nucleic acid is a sesquiterpene synthase. The host may be chosen from, for example, plants, microorganisms, bacterial cells, yeast cells, plant cells, and animal cells.

[0014] In another embodiment the invention provides a method of making at least one terpenoid comprising 1) contacting at least one acyclic pyrophosphate terpene precursor with at least one polypeptide encoded by a nucleic acid. In one embodiment, the nucleic acid is chosen from (a) a nucleic acid comprising the nucleotide sequence substantially as set out in SEQ ID NO:6, SEQ ID NO:7, SEQ ID NO:8, SEQ ID NO:9, or SEQ ID NO:10; (b) a nucleic acid encoding the polypeptide substantially set out in SEQ ID NO:1, SEQ ID NO:2, SEQ ID NO:3, SEQ ID NO:4, or SEQ ID NO:5; and (c) a nucleic acid that hybridizes to the nucleic acid of (a) or (b) under low stringency conditions, wherein the polypeptide encoded by said nucleic acid is a sesquiterpene synthase, 2) isolating at least one terpenoid produced in (1). In one embodiment, the at least one terpenoid is chosen from sesquiterpenes. In a further embodiment, the at least one acyclic pyrophosphate terpene precursor is farnesyl-pyrophosphate. The sesquiterpenes produced by the methods of the invention include, but are not limited to, bicylogermacrene, cubebol, valencene, α -cubebene, germacrene D, and δ -cadinene (Figure 3).

[0015] It is to be understood that both the foregoing general description and the following detailed description are exemplary and explanatory only and are not restrictive of the invention as claimed. Reference will now be made in detail to exemplary embodiments of the present invention.

Brief Description of the Figures

[0016] Figure 1: Example pathways for biosynthesis of isopentenyl pyrophosphate (Mevalonate pathway (A) and deoxyxylulose pathway (B)).

[0017] Figure 2: Example terpene biosynthesis from isopentenyl diphosphate.

[0018] Figure 3: Structure of example sesquiterpene compounds.

[0019] Figure 4: Central part of the alignments of the amino acid sequences of two groups of sesquiterpene synthase (Germacrene C *L. esculentum* δ -cadinene synthase (SEQ ID NO:11); (E)-beta-Farnesene *M. piperita* (SEQ ID NO:12); delta-Selinene *A. grandis* (SEQ ID NO:13); Sesquiterpene synthase *C. junos* (SEQ ID NO:14); 5-epi-Aristolochene *N. tabacum* (SEQ ID NO:15); 5-epi-Aristolochene *C. annuum* (SEQ ID NO:16); Vetispiradiene *S. tuberosum* (SEQ ID NO:17); Vetispiradiene *H. muticus* (SEQ ID NO:18); delta-Cadinene *G. arboreum* (SEQ ID NO:19); Amorpha-4,11-diene *A. annua* (SEQ ID NO:20); epi-Cedrol *A. annua* (SEQ ID NO:21); delta-Humulene *A. grandis* (SEQ ID NO:22)) and the sequence of the deduced degenerate primers (TpsVF1 (SEQ ID NO:23); TpsVF2 (SEQ ID NO:24); TpsVR3 (SEQ ID NO:25); TpsCF1 (SEQ ID NO:26); TpsCF2 (SEQ ID NO:27); TpsCR3 (SEQ ID NO:28)). The arrows below each alignment show the regions of the alignment used to design the degenerate primers and their orientation.

[0020] Figure 5: Alignment of the amino acid sequences deduced from the amplification products obtained by RT-PCR on grapefruit total RNA (GFTpsA (SEQ ID NO:29); GFTpsB (SEQ ID NO:30); and GFTpsC (SEQ ID NO:31)).

[0021] Figure 6: Amino acid sequence alignment of the sesquiterpene synthases GFTpsA (partial clone) (SEQ ID NO:32), GFTpsB (SEQ ID NO:3) , GFTpsC (SEQ ID NO:1), GFTpsD1 (SEQ ID NO:4), GFTpsD2 (SEQ ID NO:5), and GFTpsE (SEQ ID NO:2) from *C. paradisi*.

[0022] Figure 7: GC profiles of sesquiterpenes produced by recombinant grapefruit sesquiterpene synthases.

[0023] Figure 8: The amino acid and nucleotide sequences of (a) GFTpsA (SEQ ID NO:32 and SEQ ID NO:33), (b) GFTpsB (SEQ ID NO:3 and SEQ ID NO:8), (c) GFTbsC (SEQ ID NO:1 and SEQ ID NO:6), (d) GFTpsD1 (SEQ ID NO:4 and SEQ ID NO:9), (e) GFTpsD2 (SEQ ID NO:5 and SEQ ID NO:10), and (f) GFTpsE (SEQ ID NO:2 and SEQ ID NO:7).

Description of the Invention

[0024] A terpene is an unsaturated hydrocarbon based on an isoprene unit (C₅H₈) which may be acyclic or cyclic. Terpene derivatives, include but are not limited to camphor, menthol, terpineol, and borneol, geraniol. Terpenes or Terpenoid, as used herein includes terpenes and terpene derivatives, including compounds that have undergone one or more steps of functionalization such as hydroxylations, isomerizations, oxido-reductions or acylations. As used herein, a sesquiterpene is terpene based on a C₁₅ structure and includes sesquiterpenes and sesquiterpenes derivatives, including compounds that have undergone one or more steps of functionalization such as hydroxylations, isomerizations, oxido-reductions or acylations.

[0025] As used herein, a derivative is any compound obtained from a known or hypothetical compound and containing essential elements of the parent substance.

[0026] As used herein, sesquiterpene synthase is any enzyme that catalyzes the synthesis of a sesquiterpene.

[0027] The phrase "identical," "substantially identical," or "substantially as set out," means that a relevant sequence is at least 70%, 75%, 80%, 85%, 90%, 92%, 95%, 96%, 97%, 98%, or 99% identical to a given sequence. By way of example, such sequences may be allelic variants, sequences derived from various species, or they may be derived from the given sequence by

truncation, deletion, amino acid substitution or addition. For polypeptides, the length of comparison sequences will generally be at least 20, 30, 50, 100 or more amino acids. For nucleic acids, the length of comparison sequences will generally be at least 50, 100, 150, 300, or more nucleotides. Percent identity between two sequences is determined by standard alignment algorithms such as, for example, Basic Local Alignment Tool (BLAST) described in Altschul et al. (1990) J. Mol. Biol., 215:403-410, the algorithm of Needleman et al. (1970) J. Mol. Biol., 48:444-453, or the algorithm of Meyers et al. (1988) Comput. Appl. Biosci., 4:11-17.

[0028] The invention thus provides, in one embodiment, an isolated nucleic acid selected from: (a) a nucleic acid comprising the nucleotide sequence substantially as set out in SEQ ID NO:6, SEQ ID NO:7, SEQ ID NO:8, SEQ ID NO:9, or SEQ ID NO:10; (b) a nucleic acid encoding the polypeptide substantially set out in SEQ ID NO:1, SEQ ID NO:2, SEQ ID NO:3, SEQ ID NO:4, or SEQ ID NO:5; and (c) a nucleic acid that hybridizes to the nucleic acid of (a) or (b) under low stringency conditions, wherein the polypeptide encoded by said nucleic acid is a sesquiterpene synthase. In one embodiment, the defined conditions are moderate stringency conditions and in a further embodiment high stringency conditions.

[0029] As used herein, one determines whether a polypeptide encoded by a nucleic acid of the invention is a sesquiterpene synthase by the enzyme characterization assay described in the examples herein.

[0030] As used herein, the term hybridization or hybridizes under certain conditions is intended to describe conditions for hybridization and washes under which nucleotide sequences that are significantly identical or homologous to each other remain bound to each other. The conditions may be such that sequences, which are at least about 70%, such as at least about 80%, and such as at least about 85-90% identical, remain bound to each other. Definitions of low stringency, moderate, and high stringency hybridization conditions are provided herein.

[0031] Appropriate hybridization conditions can be selected by those skilled in the art with minimal experimentation as exemplified in Ausubel et al.

(1995), Current Protocols in Molecular Biology, John Wiley & Sons, sections 2, 4, and 6. Additionally, stringency conditions are described in Sambrook et al. (1989) Molecular Cloning: A Laboratory Manual, 2nd ed., Cold Spring Harbor Press, chapters 7, 9, and 11. As used herein, defined conditions of low stringency are as follows. Filters containing DNA are pretreated for 6 h at 40°C. in a solution containing 35% formamide, 5x SSC, 50 mM Tris-HCl (pH 7.5), 5 mM EDTA, 0.1% PVP, 0.1% Ficoll, 1% BSA, and 500 µg/ml denatured salmon sperm DNA. Hybridizations are carried out in the same solution with the following modifications: 0.02% PVP, 0.02% Ficoll, 0.2% BSA, 100 µg/ml salmon sperm DNA, 10% (wt/vol) dextran sulfate, and 5-20x10⁶ 32P-labeled probe is used. Filters are incubated in hybridization mixture for 18-20 h at 40°C, and then washed for 1.5 h at 55°C. In a solution containing 2x SSC, 25 mM Tris-HCl (pH 7.4), 5 mM EDTA, and 0.1% SDS. The wash solution is replaced with fresh solution and incubated an additional 1.5 h at 60°C. Filters are blotted dry and exposed for autoradiography.

[0032] As used herein, defined conditions of moderate stringency are as follows. Filters containing DNA are pretreated for 7 h at 50°C. in a solution containing 35% formamide, 5x SSC, 50 mM Tris-HCl (pH 7.5), 5 mM EDTA, 0.1% PVP, 0.1% Ficoll, 1% BSA, and 500 µg/ml denatured salmon sperm DNA. Hybridizations are carried out in the same solution with the following modifications: 0.02% PVP, 0.02% Ficoll, 0.2% BSA, 100 µg/ml salmon sperm DNA, 10% (wt/vol) dextran sulfate, and 5-20x10⁶ 32P-labeled probe is used. Filters are incubated in hybridization mixture for 30 h at 50°C, and then washed for 1.5 h at 55°C. In a solution containing 2x SSC, 25 mM Tris-HCl (pH 7.4), 5 mM EDTA, and 0.1% SDS. The wash solution is replaced with fresh solution and incubated an additional 1.5 h at 60°C. Filters are blotted dry and exposed for autoradiography.

[0033] As used herein, defined conditions of high stringency are as follows. Prehybridization of filters containing DNA is carried out for 8 h to overnight at 65°C in buffer composed of 6x SSC, 50 mM Tris-HCl (pH 7.5), 1 mM EDTA, 0.02% PVP, 0.02% Ficoll, 0.02% BSA, and 500 µg/ml denatured salmon sperm DNA. Filters are hybridized for 48 h at 65°C in the prehybridization

mixture containing 100 µg /ml denatured salmon sperm DNA and 5-20x10⁶ cpm of 32P-labeled probe. Washing of filters is done at 37°C for 1 h in a solution containing 2x SSC, 0.01% PVP, 0.01% Ficoll, and 0.01% BSA. This is followed by a wash in 0.1x SSC at 50°C for 45 minutes.

[0034] Other conditions of low, moderate, and high stringency well known in the art (e.g., as employed for cross-species hybridizations) may be used if the above conditions are inappropriate (e.g., as employed for cross-species hybridizations).

[0035] In one embodiment, a nucleic acid and/or polypeptide of the invention is isolated from a citrus, such as, for example a grapefruit or an orange. In a particular embodiment, the invention relates to certain isolated nucleotide sequences including those that are substantially free from contaminating endogenous material. The terms "nucleic acid" or "nucleic acid molecule" refer to a deoxyribonucleotide or ribonucleotide polymer in either single-or double-stranded form, and unless otherwise limited, would encompass known analogs of natural nucleotides that can function in a similar manner as naturally occurring nucleotides. A "nucleotide sequence" also refers to a polynucleotide molecule or oligonucleotide molecule in the form of a separate fragment or as a component of a larger nucleic acid. The nucleotide sequence or molecule may also be referred to as a "nucleotide probe." Some of the nucleic acid molecules of the invention are derived from DNA or RNA isolated at least once in substantially pure form and in a quantity or concentration enabling identification, manipulation, and recovery of its component nucleotide sequence by standard biochemical methods. Examples of such methods, including methods for PCR protocols that may be used herein, are disclosed in Sambrook et al., *Molecular Cloning: A Laboratory Manual*, 2nd ed., Cold Spring Harbor Laboratory, Cold Spring Harbor, NY (1989), *Current Protocols in Molecular Biology* edited by F.A. Ausubel et al., John Wiley and Sons, Inc. (1987), and Innis, M. et al., eds., *PCR Protocols: A Guide to Methods and Applications*, Academic Press (1990).

[0036] As described herein, the nucleic acid molecules of the invention include DNA in both single-stranded and double-stranded form, as well as the RNA complement thereof. DNA includes, for example, cDNA, genomic DNA, chemically synthesized DNA, DNA amplified by PCR, and combinations thereof. Genomic DNA, including translated, non-translated and control regions, may be isolated by conventional techniques, e.g., using any one of the cDNAs of the invention, or suitable fragments thereof, as a probe, to identify a piece of genomic DNA which can then be cloned using methods commonly known in the art. In general, nucleic acid molecules within the scope of the invention include sequences that hybridize to sequences of the invention under hybridization and wash conditions described above and of 5 °, 10 °, 15 °, 20 °, 25 °, or 30 ° below the melting temperature of the DNA duplex of sequences of the invention, including any range of conditions subsumed within these ranges.

[0037] In another embodiment, the nucleic acids of the invention comprises a sequence substantially as set out in SEQ ID NO:6, SEQ ID NO:7, SEQ ID NO:8, SEQ ID NO:9, or SEQ ID NO:10. In one embodiment, the nucleic acids are at least 85%, at least 90%, or at least 95% identical to nucleotides SEQ ID NO:6, SEQ ID NO:7, SEQ ID NO:8, SEQ ID NO:9, or SEQ ID NO:10. In one embodiment, the nucleic acid comprises the nucleotide sequence SEQ ID NO:6, SEQ ID NO:7, SEQ ID NO:8, SEQ ID NO:9, or SEQ ID NO:10. In a further embodiment, the nucleic acid encodes a protein that is a sesquiterpenes synthase, as demonstrated, for example, in the enzyme assay described in the examples. Nucleic acids comprising regions conserved among different species, are also provided.

[0038] In yet another embodiment, the nucleic acid comprises a contiguous stretch of at least 50, 100, 250, 500, 750 contiguous nucleotides of SEQ ID NO:6, SEQ ID NO:7, SEQ ID NO:8, SEQ ID NO:9, or SEQ ID NO:10. Such contiguous fragments of these nucleotides may also contain at least one mutation so long as the mutant sequence retains the functionality of the original sequence and the capacity to hybridize to these nucleotides under low or high stringency conditions, such as for example, moderate or high

stringency conditions. Such a fragment can be derived, for example, from nucleotide (nt) 200 to nt 1600, from nt 800 to nt 1600, from nt 1000 to nt 1600, from nt 200 to nt 1000, from nt 200 to nt 800, from nt 400 to nt 1600, or from nt 400 to nt 1000 of SEQ ID NO:6, SEQ ID NO:7, SEQ ID NO:8, SEQ ID NO:9, or SEQ ID NO:10.

[0039] As described above, polypeptides encoded by the nucleic acids of the invention are encompassed by the invention. The isolated nucleic acids of the invention may be selected from a nucleic acid encoding the polypeptide substantially set out in SEQ ID NO:1, SEQ ID NO:2, SEQ ID NO:3, SEQ ID NO:4, or SEQ ID NO:5. In one embodiment, the polypeptides are at least 85%, at least 90%, or at least 95% identical to SEQ ID NO:1, SEQ ID NO:2, SEQ ID NO:3, SEQ ID NO:4, or SEQ ID NO:5.

[0040] In one embodiment, a polypeptide of the invention comprises an amino acid sequence as set out in SEQ ID NO:1, SEQ ID NO:2, SEQ ID NO:3, SEQ ID NO:4, or SEQ ID NO:5. In another embodiment, the polypeptide comprises an amino acid sequence substantially as set out in of SEQ ID NO:1, SEQ ID NO:2, SEQ ID NO:3, SEQ ID NO:4, or SEQ ID NO:5. In yet another embodiment, the polypeptide comprises an amino acid sequence that is at least 85% identical, at least 90% or at least 95% identical to of SEQ ID NO:1, SEQ ID NO:2, SEQ ID NO:3, SEQ ID NO:4, or SEQ ID NO:5. In one embodiment, the polypeptide is a sesquiterpene synthase, as demonstrated, for example, in the enzyme assay described below.

[0041] Due to the degeneracy of the genetic code wherein more than one codon can encode the same amino acid, multiple DNA sequences can code for the same polypeptide. Such variant DNA sequences can result from genetic drift or artificial manipulation (e.g., occurring during PCR amplification or as the product of deliberate mutagenesis of a native sequence). The present invention thus encompasses any nucleic acid capable of encoding a protein derived from the SEQ ID NO:6, SEQ ID NO:7, SEQ ID NO:8, SEQ ID NO:9, or SEQ ID NO:10 or variants thereof.

[0042] Deliberate mutagenesis of a native sequence can be carried out using numerous techniques well known in the art. For example,

oligonucleotide-directed site-specific mutagenesis procedures can be employed, particularly where it is desired to mutate a gene such that predetermined restriction nucleotides or codons are altered by substitution, deletion or insertion. Exemplary methods of making such alterations are disclosed by Walder et al. (Gene 42:133, 1986); Bauer et al. (Gene 37:73, 1985); Craik (BioTechniques, January 12-19, 1985); Smith et al. (Genetic Engineering: Principles and Methods, Plenum Press, 1981); Kunkel (Proc. Natl. Acad. Sci. USA 82:488, 1985); Kunkel et al. (Methods in Enzymol. 154:367, 1987); and U.S. Patent Nos. 4,518,584 and 4,737,462.

[0043] In one embodiment, the invention provides for isolated polypeptides. As used herein, the term "polypeptides" refers to a genus of polypeptide or peptide fragments that encompass the amino acid sequences identified herein, as well as smaller fragments. Alternatively, a polypeptide may be defined in terms of its antigenic relatedness to any peptide encoded by the nucleic acid sequences of the invention. Thus, in one embodiment, a polypeptide within the scope of the invention is defined as an amino acid sequence comprising a linear or 3-dimensional epitope shared with any peptide encoded by the nucleic acid sequences of the invention.

Alternatively, a polypeptide within the scope of the invention is recognized by an antibody that specifically recognizes any peptide encoded by the nucleic acid sequences of the invention. Antibodies are defined to be specifically binding if they bind polypeptides of the invention with a K_a of greater than or equal to about 10^7 M^{-1} , such as greater than or equal to 10^8 M^{-1} .

[0044] A polypeptide "variant" as referred to herein means a polypeptide substantially homologous to a native polypeptide, but which has an amino acid sequence different from that encoded by any of the nucleic acid sequences of the invention because of one or more deletions, insertions or substitutions.

[0045] Variants can comprise conservatively substituted sequences, meaning that a given amino acid residue is replaced by a residue having similar physiochemical characteristics. Examples of conservative substitutions include substitution of one aliphatic residue for another, such as

Ile, Val, Leu, or Ala for one another, or substitutions of one polar residue for another, such as between Lys and Arg; Glu and Asp; or Gln and Asn. See Zubay, Biochemistry, Addison-Wesley Pub. Co., (1983). The effects of such substitutions can be calculated using substitution score matrices such as PAM-120, PAM-200, and PAM-250 as discussed in Altschul, (J. Mol. Biol. 219:555-65, 1991). Other such conservative substitutions, for example, substitutions of entire regions having similar hydrophobicity characteristics, are well known.

[0046] Naturally-occurring peptide variants are also encompassed by the invention. Examples of such variants are proteins that result from alternate mRNA splicing events or from proteolytic cleavage of the polypeptides described herein. Variations attributable to proteolysis include, for example, differences in the N- or C-termini upon expression in different types of host cells, due to proteolytic removal of one or more terminal amino acids from the polypeptides encoded by the sequences of the invention.

[0047] Variants of the sesquiterpenes synthases of the invention may be used to attain desired enhanced or reduced enzymatic activity, modified regiochemistry or stereochemistry, or altered substrate utilization or product distribution. A variant or site direct mutant may be made by any methods known in the art.

[0048] As stated above, the invention provides recombinant and non-recombinant, isolated and purified polypeptides, such as from citrus plants. Variants and derivatives of native polypeptides can be obtained by isolating naturally-occurring variants, or the nucleotide sequence of variants, of other or same plant lines or species, or by artificially programming mutations of nucleotide sequences coding for native citrus polypeptides. Alterations of the native amino acid sequence can be accomplished by any of a number of conventional methods. Mutations can be introduced at particular loci by synthesizing oligonucleotides containing a mutant sequence, flanked by restriction sites enabling ligation to fragments of the native sequence. Following ligation, the resulting reconstructed sequence encodes an analog having the desired amino acid insertion, substitution, or deletion. Alternatively, oligonucleotide-directed site-specific mutagenesis procedures

can be employed to provide an altered gene wherein predetermined codons can be altered by substitution, deletion or insertion.

[0049] In one embodiment, the invention contemplates: vectors comprising the nucleic acids of the invention. For example, a vector comprising at least one nucleic acid chosen from (a) a nucleic acid comprising the nucleotide sequence substantially as set out in SEQ ID NO:6, SEQ ID NO:7, SEQ ID NO:8, SEQ ID NO:9, or SEQ ID NO:10; (b) a nucleic acid encoding the polypeptide substantially set out in SEQ ID NO:1, SEQ ID NO:2, SEQ ID NO:3, SEQ ID NO:4, or SEQ ID NO:5; and (c) a nucleic acid that hybridizes to the nucleic acid of (a) or (b) under low stringency conditions, wherein the polypeptide encoded by said nucleic acid is a sesquiterpene synthase.

[0050] A vector as used herein includes any recombinant vector including but not limited to viral vectors, bacteriophages and plasmids.

[0051] Recombinant expression vectors containing a nucleic acid sequence of the invention can be prepared using well known methods. In one embodiment, the expression vectors include a cDNA sequence encoding the polypeptide operably linked to suitable transcriptional or translational regulatory nucleotide sequences, such as those derived from a mammalian, microbial, viral, or insect gene. Examples of regulatory sequences include transcriptional promoters, operators, or enhancers, mRNA ribosomal binding sites, and appropriate sequences which control transcription and translation initiation and termination. Nucleotide sequences are "operably linked" when the regulatory sequence functionally relates to the cDNA sequence of the invention. Thus, a promoter nucleotide sequence is operably linked to a cDNA sequence if the promoter nucleotide sequence controls the transcription of the cDNA sequence. The ability to replicate in the desired host cells, usually conferred by an origin of replication, and a selection gene by which transformants are identified can additionally be incorporated into the expression vector.

[0052] In addition, sequences encoding appropriate signal peptides that are not naturally associated with the polypeptides of the invention can be incorporated into expression vectors. For example, a DNA sequence for a

signal peptide (secretory leader) can be fused in-frame to a nucleotide sequence of the invention so that the polypeptides of the invention is initially translated as a fusion protein comprising the signal peptide. A signal peptide that is functional in the intended host cells enhances extracellular secretion of the expressed polypeptide. The signal peptide can be cleaved from the polypeptide upon secretion from the cell.

[0053] Fusions of additional peptide sequences at the amino and carboxyl terminal ends of the polypeptides of the invention can be used to enhance expression of the polypeptides or aid in the purification of the protein.

[0054] In one embodiment, the invention includes a host cell comprising a nucleic acid of the invention. Another embodiment of the invention is a method of making a recombinant host cell comprising introducing the vectors of the invention, into a host cell. In a further embodiment, a method of producing a polypeptide comprising culturing the host cells of the invention under conditions to produce the polypeptide is contemplated. In one embodiment the polypeptide is recovered. The methods of invention include methods of making at least one sesquiterpene synthase of the invention comprising culturing a host cell comprising a nucleic acid of the invention, and recovering the sesquiterpene synthase accumulated.

[0055] Suitable host cells for expression of polypeptides of the invention include prokaryotes, yeast or higher eukaryotic cells. Appropriate cloning and expression vectors for use with bacterial, fungal, yeast, and mammalian cellular hosts are described, for example, in Pouwels et al., *Cloning Vectors: A Laboratory Manual*, Elsevier, New York, (1985). Cell-free translation systems could also be employed to produce the disclosed polypeptides using RNAs derived from DNA constructs disclosed herein.

[0056] Prokaryotes include gram negative or gram positive organisms, for example, *E. coli* or *Bacilli*. Suitable prokaryotic host cells for transformation include, for example, *E. coli*, *Bacillus subtilis*, *Salmonella typhimurium*, and various other species within the genera *Pseudomonas*, *Streptomyces*, and *Staphylococcus*. In a prokaryotic host cell, such as *E. coli*, the polypeptides can include a N-terminal methionine residue to facilitate expression of the

recombinant polypeptide in the prokaryotic host cell. The N-terminal methionine can be cleaved from the expressed recombinant polypeptide.

[0057] Examples of useful expression vectors for prokaryotic host cells include those derived from commercially available plasmids such as the cloning vector pET plasmids (Novagen, Madison, WI, USA) or yet pBR322 (ATCC 37017). pBR322 contains genes for ampicillin and tetracycline resistance and thus provides simple means for identifying transformed cells. To construct an expression vector using pBR322, an appropriate promoter and a DNA sequence encoding one or more of the polypeptides of the invention are inserted into the pBR322 vector. Other commercially available vectors include, for example, pKK223-3 (Pharmacia Fine Chemicals, Uppsala, Sweden) and pGEM-1 (Promega Biotec, Madison, WI, USA). Other commercially available vectors include those that are specifically designed for the expression of proteins; these would include pMAL-p2 and pMAL-c2 vectors that are used for the expression of proteins fused to maltose binding protein (New England Biolabs, Beverly, MA, USA).

[0058] Promoter sequences commonly used for recombinant prokaryotic host cell expression vectors include bacteriophage T7 promoter (Studier F.W. and Moffatt B.A., J. Mol. Biol. 189:113, 1986), β -lactamase (penicillinase), lactose promoter system (Chang et al., Nature 275:615, 1978; and Goeddel et al., Nature 281:544, 1979), tryptophan (trp) promoter system (Goeddel et al., Nucl. Acids Res. 8:4057, 1980; and EP-A-36776), and tac promoter (Maniatis, Molecular Cloning: A Laboratory Manual, Cold Spring Harbor Laboratory, p. 412, 1982). A particularly useful prokaryotic host cell expression system employs a phage λ PL promoter and a cl857ts thermolabile repressor sequence. Plasmid vectors available from the American Type Culture Collection ("ATCC"), which incorporate derivatives of the PL promoter, include plasmid pHUB2 (resident in E. coli strain JMB9 (ATCC 37092)) and pPLc28 (resident in E. coli RR1 (ATCC 53082)).

[0059] Polypeptides of the invention can also be expressed in yeast host cells, preferably from the Saccharomyces genus (e.g., S. cerevisiae). Other genera of yeast, such as Pichia or Kluyveromyces (e.g. K. lactis), can also be

employed. Yeast vectors will often contain an origin of replication sequence from a 2 μ yeast plasmid, an autonomously replicating sequence (ARS), a promoter region, sequences for polyadenylation, sequences for transcription termination, and a selectable marker gene. Suitable promoter sequences for yeast vectors include, among others, promoters for metallothionine, 3-phosphoglycerate kinase (Hitzeman et al., J. Biol. Chem. 255:2073, 1980), or other glycolytic enzymes (Hess et al., J. Adv. Enzyme Reg. 7:149, 1968; and Holland et al., Biochem. 17:4900, 1978), such as enolase, glyceraldehyde-3-phosphate dehydrogenase, hexokinase, pyruvate decarboxylase, phosphofructokinase, glucose-6-phosphate isomerase, 3-phosphoglycerate mutase, pyruvate kinase, triosephosphate isomerase, phosphoglucose isomerase, and glucokinase. Other suitable vectors and promoters for use in yeast expression are further described in Hitzeman, EPA-73,657 or in Fleer et. al., Gene, 107:285-195 (1991); and van den Berg et. al., Bio/Technology, 8:135-139 (1990). Another alternative is the glucose-repressible ADH2 promoter described by Russell et al. (J. Biol. Chem. 258:2674, 1982) and Beier et al. (Nature 300:724, 1982). Shuttle vectors replicable in both yeast and E. coli can be constructed by inserting DNA sequences from pBR322 for selection and replication in E. coli (Ampr gene and origin of replication) into the above-described yeast vectors.

[0060] One embodiment of the invention is a non-human organism modified to harbor a nucleic acid of the invention. The non-human organism and/or host cell may be modified by any methods known in the art for gene transfer including, for example, the use of deliver devices such as lipids and viral vectors, naked DNA, electroporation and particle-mediated gene transfer. In one embodiment, the non-human organism is a plant, insect or microorganism.

[0061] For example, in one embodiment the invention provides a method of making at least one sesquiterpene synthase comprising culturing a host modified to contain at least one nucleic acid under conditions conducive to the production of said at least one sesquiterpene synthase wherein said at least one nucleic acid is chosen from (a) a nucleic acid comprising the nucleotide

sequence substantially as set out in SEQ ID NO:6, SEQ ID NO:7, SEQ ID NO:8, SEQ ID NO:9, or SEQ ID NO:10; (b) a nucleic acid encoding the polypeptide substantially set out in SEQ ID NO:1, SEQ ID NO:2, SEQ ID NO:3, SEQ ID NO:4, or SEQ ID NO:5; and (c) a nucleic acid that hybridizes to the nucleic acid of (a) or (b) under low stringency conditions, wherein the polypeptide encoded by said nucleic acid is a sesquiterpene synthase.

[0062] In a further embodiment, the host is a plant such as tobacco, animal or microorganism also including but not limited to bacterial cells, yeast cells, plant cells, and animal cells. As used herein, plant cells and animal cells include the use of plants and animals as a host. For example, in some embodiments of the invention, expression is in a genetically modified non-human organism.

[0063] In one embodiment, mammalian or insect host cell culture systems are employed to express recombinant polypeptides of the invention. Baculovirus systems for production of heterologous proteins in insect cells are reviewed by Luckow and Summers, *Bio/Technology* 6:47 (1988). Established cell lines of mammalian origin also can be employed. Examples of suitable mammalian host cell lines include the COS-7 line of monkey kidney cells (ATCC CRL 1651) (Gluzman et al., *Cell* 23:175, 1981), L cells, C127 cells, 3T3 cells (ATCC CCL 163), Chinese hamster ovary (CHO) cells, HeLa cells, and BHK (ATCC CRL 10) cell lines, and the CV-1/EBNA-1 cell line (ATCC CRL 10478) derived from the African green monkey kidney cell line CV1 (ATCC CCL 70) as described by McMahan et al. (*EMBO J.* 10: 2821, 1991).

[0064] Established methods for introducing DNA into mammalian cells have been described (Kaufman, R.J., *Large Scale Mammalian Cell Culture*, 1990, pp. 15-69). Additional protocols using commercially available reagents, such as Lipofectamine (Gibco/BRL) or Lipofectamine-Plus, can be used to transfect cells (Felgner et al., *Proc. Natl. Acad. Sci. USA* 84:7413-7417, 1987). In addition, electroporation can be used to transfect mammalian cells using conventional procedures, such as those in Sambrook et al. *Molecular Cloning: A Laboratory Manual*, 2 ed. Vol. 1-3, Cold Spring Harbor Laboratory Press, 1989). Selection of stable transformants can be performed using

resistance to cytotoxic drugs as a selection method. Kaufman et al., Meth. in Enzymology 185:487-511, 1990, describes several selection schemes, such as dihydrofolate reductase (DHFR) resistance. A suitable host strain for DHFR selection can be CHO strain DX-B11, which is deficient in DHFR (Urlaub and Chasin, Proc. Natl. Acad. Sci. USA 77:4216-4220, 1980). A plasmid expressing the DHFR cDNA can be introduced into strain DX-B11, and only cells that contain the plasmid can grow in the appropriate selective media.

[0065] Transcriptional and translational control sequences for mammalian host cell expression vectors can be excised from viral genomes. Commonly used promoter sequences and enhancer sequences are derived from polyoma virus, adenovirus 2, simian virus 40 (SV40), and human cytomegalovirus. DNA sequences derived from the SV40 viral genome, for example, SV40 origin, early and later promoter, enhancer, splice, and polyadenylation sites can be used to provide other genetic elements for expression of a structural gene sequence in a mammalian host cell. Viral early and late promoters are particularly useful because both are easily obtained from a viral genome as a fragment, which can also contain a viral origin of replication (Fiers et al., Nature 273:113, 1978; Kaufman, Meth. in Enzymology, 1990).

[0066] There are several methods known in the art for the creation of transgenic plants. These include, but are not limited to: electroporation of plant protoplasts, liposome-mediated transformation, polyethylene-glycol-mediated transformation, microinjection of plant cells, and transformation using viruses. In one embodiment, direct gene transfer by particle bombardment is utilized.

[0067] Direct gene transfer by particle bombardment provides an example for transforming plant tissue. In this technique a particle, or microprojectile, coated with DNA is shot through the physical barriers of the cell. Particle bombardment can be used to introduce DNA into any target tissue that is penetrable by DNA coated particles, but for stable transformation, it is imperative that regenerable cells be used. Typically, the particles are made of

gold or tungsten. The particles are coated with DNA using either CaCl₂ or ethanol precipitation methods which are commonly known in the art.

[0068] DNA coated particles are shot out of a particle gun. A suitable particle gun can be purchased from Bio-Rad Laboratories (Hercules, CA). Particle penetration is controlled by varying parameters such as the intensity of the explosive burst, the size of the particles, or the distance particles must travel to reach the target tissue.

[0069] The DNA used for coating the particles may comprise an expression cassette suitable for driving the expression of the gene of interest that will comprise a promoter operably linked to the gene of interest.

[0070] Methods for performing direct gene transfer by particle bombardment are disclosed in U.S. Patent 5,990,387 to Tomes et al.

[0071] In one embodiment, the cDNAs of the invention may be expressed in such a way as to produce either sense or antisense RNA. Antisense RNA is RNA that has a sequence which is the reverse complement of the mRNA (sense RNA) encoded by a gene. A vector that will drive the expression of antisense RNA is one in which the cDNA is placed in "reverse orientation" with respect to the promoter such that the non-coding strand (rather than the coding strand) is transcribed. The expression of antisense RNA can be used to down-modulate the expression of the protein encoded by the mRNA to which the antisense RNA is complementary. Vectors producing antisense RNA's could be used to make transgenic plants, as described above.

[0072] In one embodiment, transfected DNA is integrated into a chromosome of a non-human organism such that a stable recombinant systems results. Any chromosomal integration method known in the art may be used in the practice of the invention, including but not limited to, recombinase-mediated cassette exchange (RMCE), viral site specific chromosomal insertion, adenovirus, and pronuclear injection.

[0073] A further embodiment of the invention is methods of making terpenoids and sesquiterpene compounds, for example, using the nucleotides and polypeptides of the invention. Examples include methods of making at least one terpenoid comprising contacting at least one acyclic pyrophosphate

terpene precursor with at least one polypeptide encoded by a nucleic acid chosen from (a) a nucleic acid comprising the nucleotide sequence substantially as set out in SEQ ID NO:6, SEQ ID NO:7, SEQ ID NO:8, SEQ ID NO:9, or SEQ ID NO:10; (b) a nucleic acid encoding the polypeptide substantially set out in SEQ ID NO:1, SEQ ID NO:2, SEQ ID NO:3, SEQ ID NO:4, or SEQ ID NO:5; and (c) a nucleic acid that hybridizes to the nucleic acid of (a) or (b) under low stringency conditions, wherein the polypeptide encoded by said nucleic acid is a sesquiterpene synthase, and isolating at least one terpenoid produced. Another example is a method of making at least one terpenoid comprising contacting at least one acyclic pyrophosphate terpene precursor with at least one polypeptide substantially set out in SEQ ID NO:1, SEQ ID NO:2, SEQ ID NO:3, SEQ ID NO:4, or SEQ ID NO:5 and isolating at least one terpenoid produced.

[0074] As used herein an acyclic pyrophosphate terpene precursor is any acyclic pyrophosphate compound that is a precursor to the production of at least one terpene including but not limited to geranyl-pyrophosphate (GPP), farnesyl-pyrophosphate (FPP) and geranylgeranyl-pyrophosphate (GGPP).

[0075] In one embodiment, the at least one terpenoid is chosen from sesquiterpenes. In one embodiment, the at least one acyclic pyrophosphate terpene precursor is farnesyl-pyrophosphate. In a further embodiment, the at least one sesquiterpene is chosen from bicylogermacrene((E,E)-3,7,11,11-tetramethyl-bicyclo[8.1.0]undeca-2,6-diene), cubebol ((1R,4S,5R,6R,7S,10R)-7-isopropyl-4,10-dimethyl-tricyclo[4.4.0.0(1,5)]decan-4-ol, valencene ((+)-(1R)-1,2,3,5,6,7,8,8A-octahydro-7-isopropenyl-1@,8A@-dimethylnaphthalene), α -cubebene, germacrene D, and δ - cadinene(rel-(1R,8AS)-1,2,3,5,6,8A-hexahydro-1-isopropyl-4,7-dimethylnaphthalene) (Figure 2). The terpenoids of the invention may be isolated by any method used in the art including but not limited to chromatography, extraction and distillation.

[0076] In one embodiment, the distribution of products or the actual products formed may be altered by varying the pH at which the synthase contacts the acyclic pyrophosphate terpene precursor, such as, for example,

farnesyl-pyrophosphate. In one embodiment, the pH is 7. In a further embodiment the pH is less than 7, such as, for example, 6, 5, 4, and 3.

[0077] Also within the practice of the invention is an organism (*e.g.*, micro-organism or plant) that is used to construct a platform for high level production of a substrate of sesquiterpene synthases (*e.g.*, FPP) and the introduction of a nucleic acid of the invention into the organism. For example, at least one nucleic acid of the invention that encodes a sesquiterpene synthase is incorporated into a non-human organism that produces FPP thereby effecting conversion of FPP to a sesquiterpene, and the subsequent metabolic production of the sesquiterpene. In one embodiment, this results in a platform for the high level production of sesquiterpenes.

[0078] In one embodiment, the nucleic acids of the invention are used to create other nucleic acids coding for sesquiterpene synthases. For example, the invention provides for a method of identifying a sesquiterpene synthases comprising constructing a DNA library using the nucleic acids of the invention, screening the library for nucleic acids which encode for at least one sesquiterpene synthase. The DNA library using the nucleic acids of the invention may be constructed by any process known in the art where DNA sequences are created using the nucleic acids of the invention as a starting point, including but not limited to DNA shuffling. In such a method, the library may be screened for sesquiterpene synthases using a functional assay to find a target nucleic acid that encodes a sesquiterpene synthase. The activity of a sesquiterpene synthase may be analyzed using, for example, the methods described herein. In one embodiment, high through put screening is utilized to analyze the activity of the encoded polypeptides.

[0079] As used herein a "nucleotide probe" is defined as an oligonucleotide or polynucleotide capable of binding to a target nucleic acid of complementary sequence through one or more types of chemical bonds, through complementary base pairing, or through hydrogen bond formation. As described above, the oligonucleotide probe may include natural (*ie.* A, G, C, or T) or modified bases (7-deazaguanosine, inosine, etc.). In addition, bases in a nucleotide probe may be joined by a linkage other than a

phosphodiester bond, so long as it does not prevent hybridization. Thus, oligonucleotide probes may have constituent bases joined by peptide bonds rather than phosphodiester linkages.

[0080] A "target nucleic acid" herein refers to a nucleic acid to which the nucleotide probe or molecule can specifically hybridize. The probe is designed to determine the presence or absence of the target nucleic acid, and the amount of target nucleic acid. The target nucleic acid has a sequence that is complementary to the nucleic acid sequence of the corresponding probe directed to the target. As recognized by one of skill in the art, the probe may also contain additional nucleic acids or other moieties, such as labels, which may not specifically hybridize to the target. The term target nucleic acid may refer to the specific nucleotide sequence of a larger nucleic acid to which the probe is directed or to the overall sequence (e.g., gene or mRNA). One skilled in the art will recognize the full utility under various conditions.

[0081] Other than in the operating example, or where otherwise indicated, all numbers expressing quantities of ingredients, reaction conditions, and so forth used in the specification and claims are to be understood as being modified in all instances by the term "about." Accordingly, unless indicated to the contrary, the numerical parameters set forth in the specification and claims are approximations that may vary depending upon the desired properties sought to be obtained by the present invention. At the very least, and not as an attempt to limit the application of the doctrine of equivalents to the scope of the claims, each numerical parameter should be construed in light of the number of significant digits and ordinary rounding approaches.

[0082] Notwithstanding that the numerical ranges and parameters setting forth the broad scope of the invention are approximations, the numerical values set forth in the specific examples are reported as precisely as possible. Any numerical value, however, inherently contains certain errors necessarily resulting from the standard deviation found in their respective testing measurements. The following examples are intended to illustrate the invention without limiting the scope as a result. The percentages are given on a weight basis.

[0083] The following examples are intended to illustrate the invention without limiting the scope as a result.

Examples

Material

[0084] A grapefruit (*Citrus paradisi*) flavedo was used as starting material for the experiments described herein. The flavedo (external, colored portion of the fruit peel) contains the oil glands that are the site of terpene biosynthesis. The grapefruit flavedo was prepared at Simone Gatto (Sicily) from freshly picked ripening fruits. The flavedo (3-4 mm thickness) was cut-off, immediately frozen and kept frozen during the transport and all subsequent steps in order to prevent from degradation.

Example 1: Isolating Sesquiterpene Synthase cDNA using RT-PCR

[0085] The deduced amino-acid sequences of plant sesquiterpene synthases were aligned to identify conserved regions and design plant sesquiterpene synthases-specific oligonucleotides. In order to obtain better sequence homology, the sequences were separated into two groups (Figure 4). The first group contained the sequences of the Germacrene C synthase from *Lycopersicon esculentum* cv. VFNT cherry (Colby et al, 1998), the (E)- β -farnesene synthase from *Mentha x piperita* (Crock et al, 1997), the δ -selinene synthase from *Abies grandis* (Steele et al, 1998), a sesquiterpene synthase from *Citrus junos* (GenBank accession no. AF288465) the 5-epi aristolochene synthases from *Nicotiana tabacum* (Facchini and Chappell, 1992) and from *Capsicum annuum* (Back et al, 1998), the vetispiradiene synthases from *Solanum tuberosum* and from *Hyoscyamus muticus* (Back and Chappel, 1995). The second group contained sequences of the (+)- δ -cadinene synthases from *Gossypium arboreum* (Chen et al. 1995), the amorpho-4,11-diene synthase (Mercke et al, 2000) and the epi-cedrol synthase (Merck et al, 1999) from *Artemisia annua* and the γ -humulene synthase from *Abies grandis* (Steele et al, 1998). The highest sequence homology was found in the central

part of the sequences. Three regions containing sufficiently conserved amino-acids were selected and degenerated oligonucleotides specific for these regions were designed (i.e. two forward and one reverse primers were deduced from each alignment) (Figure 4).

[0086] RT-PCR was performed using total RNA from grapefruit flavedo prepared by the Hot Borate technique and the different combination of the forward and reverse degenerated primers. The Hot Borate method for total RNA extraction was adapted from Wan and Wilkins (Wan et al. (1994) *Anal. Biochem.* 223, 7-12.). Tissues were crushed to a fine powder in liquid nitrogen using a mortar and pestle. The powder was added to 5 ml extraction buffer (200 mM borate, 30 mM EGTA, 10 mM DTT, 1% SDS, 1% NA deoxycholate, 2% PVP, 0.5% nonidet NP-40) preheated at 80°C. The mixture was homogenized using an UltraturaxTM homogenizer and filtered through two layer of MiraclothTM filter (Calbiochem). The mixture was incubated 90 minutes at 42°C in the presence of 0.5 mg/ml proteinase K (for protein/ribonuclease digestion). KCl was then added to 1M final concentration and, after 1 hour incubation on ice, the mixture was placed in a centrifuge for 10 min at 10000g and 4°C. The supernatant was recovered and 1/3 volume of 8M LiCl was added. The mixture was incubated over night at 4°C and placed in a centrifuge for 20 minutes at 10000g and 4°C. The supernatant was discarded and, the pellet washed with 2M LiCl and centrifuged again as before. The pellet was then resuspended in RNase-free distilled water, and 0.15 vol of 2 M potassium acetate solution and 2.5 volumes absolute ethanol were added. The RNA were precipitated by incubating 2 hours at -20°C and pelleted by centrifugation as before. The RNA pellet was washed with 80% ethanol and resuspended in RNase free distilled water.

[0087] The concentration of RNA was estimated from the OD at 260 nm. The integrity of the RNA was evaluated on an agarose gel by verifying the integrity of the ribosomal RNA bands.

[0088] RT-PCR was performed using the Qiagen OneStep RT-PCR Kit and an Eppendorf Mastercycler gradient thermal cycler. Typical reaction mixtures contained 10 µl 5X Qiagen OneStep RT-PCR buffer, 400 µM each

dNTP, 400 nM each primer, 2 μ l Qiagen OneStep RT-PCR Enzyme Mix, 1 μ l RNasin® Ribonuclease Inhibitor (Promega Co.) and 1 μ g total RNA in a final volume of 50 μ l. The thermal cycler conditions were: 30 min at 50°C (reverse transcription); 15 min at 95°C (DNA polymerase activation); 40 cycles of 45 sec at 94°C, 10 sec at 42°C to 45°C (depending on the primer used), 45 sec to 90 sec (depending on the size of the DNA fragment to be amplified) at 72°C; and 10 min at 72°C.

[0089] The size of the PCR products was evaluated on a 1% agarose gel. The bands corresponding to the expected size were excised from the gel, purified using the QIAquick® Gel Extraction Kit (Qiagen) and cloned in the pCR®2.1-TOPO vector using the TOPO TA cloning Kit (Invitrogen). Inserted cDNAs were then subject to DNA sequencing and the sequence compared against the GenBank non redundant protein database (NCBI) using the BLASTX algorithm (Altschul et al 1990).

[0090] The analysis by DNA sequencing and the Blast search of the PCR products with expected length (80 to 240 bp in size) revealed fragments of three different sesquiterpene synthases, which were named GFTpsA, GFtpsB and GFTpsC. The 180-bp GFTpsA fragment was amplified with the primers TpsVF1 and TpsVR3, the 115-bp GFtpsB fragment was amplified with the primers TpsVF2 and TpsVR3, and the 115-bp GFTpsA fragment was amplified with the primers TpsVF1 and TpsVR3. The deduced amino-acid sequences revealed significant differences between these three fragments (Figure 5).

Example 2: Isolating Sesquiterpene Synthase cDNA using 5'/3'-RACE

[0091] To isolate the full-length sequences of the sesquiterpene synthases, a 5'/3'-RACE approach was first used. cDNA was synthesized using Marathon™ cDNA Amplification Kit (Clontech) and starting from 1 μ g mRNA purified from total RNA prepared with the Hot Borate technique. The quality of the synthesized cDNA was poor, essentially small size cDNAs were obtained (average size of 0.5 Kb). However, using this cDNA, the 3'-end of the GFTpsB and GFTpsC were obtained using the gene specific primers

GFTpsBRF1 and GFTpsBRF2 for GFTpsB and the gene specific primers GFTpsCRF1 and GFTpsCRF2 for GFTpsC (see Table 1). mRNA prepared by the guanidinium-thiocyanate/phenol extraction method gave higher quality cDNA with an average size of 2 Kb and allowed the isolation of the 5'-end sequence of GFTpsC using the gene specific primers GFTpsCRR1 and GFTpsRR2 (see Table 1), completing the full-length sequence of this clone. The 5'-end of GFTpsB and the 5'-end and 3'-end of GFTpsA could not be obtained by this approach.

[0092] The guanidinium-thiocyanate/phenol extraction method was based on the technique described by Chomczynski and Sacchi using the RNAClean™ solution from ThermoHybaid (Chomczynski, P., and Sacchi, N., (1987) Anal. Biochem. 162, 156-159.). Briefly, 2 g of frozen tissues was crushed to a fine powder in liquid nitrogen using a mortar and pestle. The powder was transferred to 20 ml RNAClean™ solution and the suspension was homogenized using an Ultraturax™ homogenizer and filtered through Miracloth™ filter (Calbiochem). After addition of 0.1 volume of chloroform, the tube was placed on ice and centrifuged 20 min at 12000g and 4°C. The upper aqueous phase was recovered and one volume of isopropanol was added. After 20 min. incubation at -20°C, the sample was centrifuged 20 min. at 12000g and 4°C. The large white pellet obtained was washed with 70% ethanol and dried at room temperature. This pellet, containing the total RNA, was immediately subject to mRNA purification by oligodT-cellulose affinity chromatography using the FastTrack® 2.0 mRNA isolation Kit (Invitrogen). The manufacturer's protocol was followed except that after resuspension of the total RNA in the lysis buffer, the sample was heated at 100°C instead of 65°C.

[0093] 3' and 5' rapid amplification of cDNA ends (RACE) were performed using Marathon™ cDNA Amplification Kit (Clontech). The procedure began with the first-strand cDNA synthesis starting from mRNA using an oligo(dT) primer. After second-strand synthesis, specific adaptors were ligated to the double stranded cDNA (ds cDNA) ends. This procedure provided an uncloned library of adaptor-ligated ds cDNA. Purified grapefruit mRNA (1 µg)

was used as starting material. The quality and quantity of cDNA was evaluated on an agarose gel.

[0094] The 3'- or 5'-end of the specific cDNAs were amplified with Advantage® 2 Polymerase Mix using a combination of gene- and adaptor-specific oligonucleotides. Typical RACE reaction mixtures contained, in a final volume of 50 µl, 5 µl 10X cDNA PCR Reaction Buffer (clontech), 200 nM each dNTP, 1 µl Advantage® 2 Polymerase Mix, 200 µM adaptor-specific primer (Clontech), 200 µM gene-specific primer (see Table 1) and 5 µl of 50 to 250 fold diluted adaptor-ligated cDNA. Amplification was performed on an Eppendorf Mastercycler gradient thermal cycler. The thermal Cycling conditions were as follows: 1 min at 94°C, 5 cycles of 30 sec at 94°C and 2 to 4 min at 72°C, 5 cycles of 30 sec at 94°C and 2 to 4 min at 70°C, 20 cycles of 30 sec at 94°C and 2 to 4 min at 68°C. When necessary a second round of amplification was performed using a nested adaptor-specific primer (Clontech) and a nested gene-specific primer.

[0095] The amplification products were evaluated, sub-cloned, and the sequence analyzed as above for the RT-PCR products.

TABLE 1: The following primers were used in the 3'/5'-RACE experiments:

Name.	Description.	Sequence (5' to 3').
GFTpsARF1 (SEQ ID NO:33)	3'-RACE forward primer.	CTGGGAGTGCCTATGAGCT CAATTTGG
GFTpsARF2 (SEQ ID NO:34)	GFTpsA 3'-RACE forward nested primer.	GTAGAATTTTTGCATCCAAAG TGGTGTGC
GFTpsARR1 (SEQ ID NO:35)	GFTpsA 5'-RACE reverse primer.	CACACCACTTTGGATGCAAA AATTCATC
GFTpsARR2 (SEQ ID NO:36)	GFTpsA 5'-RACE reverse nested primer.	CCAAATTGGGCTCATAGGAC ACTCCCAG
GFTpsBRF1 (SEQ ID NO:37)	GFTpsB 3'-RACE forward primer.	TAGGGACGTATTTTGAACCA AAGTAC
GFTpsBRF2 (SEQ ID NO:38)	GFTpsB 3'-RACE forward nested primer.	AAATAATGACCAAAACAATTT ACACGG
GFTpsBRR1	GFTpsB 5'-RACE reverse primer.	GCACTTTCATGTATTCTGGAA

(SEQ ID NO:39)		G
GFTpsBRR2 (SEQ ID NO:40)	GFTpsB 5'-RACE reverse nested primer.	GTTTGAGCTCTTCAAAGAAA CC
GFTpsCRF1 (SEQ ID NO:41)	GFTpsC 3'-RACE forward primer.	AATGGGAGTGTATTTTGAGC CTCGATACTCC
GFTpsCRF2 (SEQ ID NO:42)	GFTpsC 3'-RACE forward nested primer.	GATATTTTCCAAAGTAATTGC AATGGCATCC
GFTpsCRR1 (SEQ ID NO:43)	GFTpsC 5'-RACE reverse primer.	GTTGCTAATATCCCACCTTTT GATAGC
GFTpsCRR2 (SEQ ID NO:44)	GFTpsC 5'-RACE reverse nested primer.	AAGTGTGCCATAGGCGTCGT AGG
GFTpsDRR1 (SEQ ID NO:45)	GFTpsD 5'-RACE reverse primer.	CTGTTCCGCAAGCTTAGGGG TTACATG
GFTpsDRR2 (SEQ ID NO:46)	GFTpsD 5'-RACE reverse nested primer.	CTGAGCTACCAATGACTTCA GGTGAGTGG
GFTpsERR1 (SEQ ID NO:47)	GFTpsE 5'-RACE reverse primer.	CAATTTTGCCATACACATCAT AGATATCATC
GFTpsERR2 (SEQ ID NO:48)	GFTpsE 5'-RACE reverse nested primer.	AACAGAAGTCATGGAGATCA CTTTCGTC
GFTpsERR3 (SEQ ID NO:49)	GFTpsE 5'-RACE reverse primer.	CGCAAGAGATGTTTTAAAGTT CCCATCC
GFTpsERR4 (SEQ ID NO:50)	GFTpsE 5'-RACE reverse nested primer.	TGAACATCAGCGGAAATTTTA TAGCC

[0096] The partial GFTpsB cDNA obtained by 3'-RACE revealed high sequence identity to a putative terpene synthase cDNA found in the public databases (GeneBank accession no. AF288465) and isolated from *Citrus junos*. Primers specific for the sequence of this terpene synthase were designed: one pair of forward and reverse primers (junosF1 and junosR1) designed against the non-coding region of the *C. junos* terpene synthase and one pair of forward and reverse primers (junosF2 and junos R2) designed in the coding region including the start and stop codons. PCR on the grapefruit Marathon™ cDNA library using the primers junosF1 and junosR1 produced no amplicon. Using the junosF2 and junosR2 primers a fragment of 1.6 Kb was amplified. DNA sequencing confirmed this PCR product as being a 1669-bp full-length sesquiterpene synthase of the GFTpsB clone. (Figure 6).

Example 3: cDNA library screening and EST sequencing

[0097] In order to obtain the full-length cDNA of the partial clones obtained by the PCR approach, a cDNA library prepared from grapefruit flavedo mRNA was constructed.

[0098] cDNA synthesis and library construction were performed using the Uni-ZAP® XR library construction Kit (Stratagene) according to manufacturer's protocol starting from 7.5 µg grapefruit flavedo mRNA (prepared by the Guanidinium-Thiocyanate/Phenol method). The original titer of the library was 2×10^7 PFU (plaques forming units) and the average insert size was 1.1 Kb.

[0099] Two approaches were used to isolate sesquiterpene synthases encoding cDNAs from the cDNA library : EST sequencing and screening using a DNA probe. For EST (expressed sequence tag) sequencing, a fraction of the library was used to excise the pBluescript phagemid from the Uni-ZAP XR vector according to Stratagene's mass excision protocol. Resulting transformed bacterial colonies (576) were randomly picked and the plasmid purified. One sequencing reaction was performed for each clone using the T3 primer. The sequences were first edited to remove vector sequences and compared against the GenBank non redundant protein database (NCBI) using the BLASTX algorithm (Altschul et al 1990).

[00100] The library was screened with digoxigenin (DIG)-labeled DNA probes. The probes were synthesized by incorporation of DIG-dUTP into a DNA fragment by PCR using the PCR DIG (digoxigenin) Probe Synthesis Kit (Roche Diagnostics). A 149-bp GFTpsA-derived DNA probe was amplified from an aliquot of the library using the forward primer GFTpsAproF (SEQ ID NO:51) (5'-ACGATTTAGGCTTCCCTAAAAAGG-3') and the reverse primer GFTpsAproR (SEQ ID NO:52) (5'-TATTATGGAATATTATGCACACCAC-3'). A 1036-bp GFTpsB-derived probe was amplified from the pET-GFTpsB2-2 plasmid using the forward primer junosF2 (SEQ ID NO:53) (5'-AAATGTCCGCTCAAGTTCTAGCAACGG-3') and the reverse primer GFTpsBRR2 (SEQ ID NO:54) (5'-GTTTGAGCTCTTCAAAGAAACC-3'). A

1008-bp GFTpsC-derived DNA probe was amplified from the pET-GFTpsC plasmid using the forward primer GFTpsCpetF1 (SEQ ID NO:55) (5'-ATGGCACTTCAAGATTCAGAAGTTCC-3') and the reverse primer GFTpsCRR1 (SEQ ID NO:56) (5'-GTTGCTAATATCCACCTTTTGATAGC-3').

[00101] The probes were hybridized to plaques lifts, prepared from plates containing 5,000 to 25,000 PFU, at 40°C in Dig Easy Hyb hybridization solution (Roche Diagnostics). The detection of the probe-target hybrids on the membranes was performed by chemiluminescence using Anti-Digoxigenin-Alkaline Phosphatase (Roche Diagnostics) and CDP-Star alkaline phosphate substrate (Roche Diagnostics), and the visualization was made on a VersaDoc Imaging System (BioRad).

[00102] Phages from positives signals were cored from the agar plates and subject to secondary and if necessary to tertiary screening to achieve single plaques positive signals. The positive isolates were in vivo excised and the insert sequenced as described above.

[00103] The library was screened using DNA probes prepared from GFTpsA, GFTpsB and GFTpsC. This approach yielded three different sesquiterpene synthase cDNAs. Two of them were previously found clones: one clone, named GF2-30-1, was a 5'-end 300-bp truncated form of the GFTpsC cDNA; the second clone, named 9-13-6, was a partial clone of GFTpsA that was truncated at its 5'-end by approximately 168-bp as judged by comparison to other sesquiterpene synthases. The 9-13-6 clone provided 618-bp additional 5'-end sequence information compared to the above mentioned partial GFTpsA clone obtained by RT-PCR. At its 3'-end, the 9-13-6 clone was also incomplete. Approximately 680 nucleotides were missing and were replaced by a 600-bp fragment of no defined function. The third sesquiterpene synthase encoding cDNA obtained by screening, GF2-5-11, encoded a new sesquiterpene synthase that was named GFTpsD. This clone was truncated at the 5'-end, but the missing 414-bp was recovered by 5'-RACE using the primers described in Table 1. The full-length GFTpsD was then amplified from Marathon™ cDNA library and cloned in the bacterial

expression vector as described above. Analysis of the DNA sequence of several full-length GFTpsD cDNAs revealed that two closely related sesquiterpene synthases with minor sequence differences were present, they were named GFTpsD1 and GFTpsD2 (Figure 6). The deduced amino-acid sequence of these two variants differed from each other by 4 residues.

[00104] For the EST sequencing approach, 576 clones were sequenced. Among them, only three clones encoded putative terpene-synthases like proteins and more precisely, two different sesquiterpene synthase-like and one monoterpene synthase-like proteins. One of the two sesquiterpene synthase-like clones (clone GF002-G3) was the previously identified clone GFTpsD1. The second (clone GF006-G7) was a truncated cDNA encoding a new sesquiterpene synthase that was named GFTpsE. This clone was again 5'-end truncated (by approximately 800 bp) and the missing fragment could be amplified by 5'-RACE in two stages as follows. A first 5'-RACE using the primers GFTpsERR1 and GFTpsERR2 (see Table 1) provided 500 additional 5'-end nucleotides and a second 5'-RACE using the primers GFTpsERR3 and GFTpsERR4 (see Table 1) provided the missing 5'-end DNA sequence to reconstitute the full-length GFTpsE cDNA (Figure 6).

Example 4: Construction of Plasmids and Enzyme expression

Construction of expression plasmids.

[00105] The cDNA were sub-cloned in the pET11a expression plasmid (Novagen) for functional expression of the sesquiterpene synthases. For GFTpsB, GFTpsD and GFTpsE, the full-length cDNAs were amplified by PCR to introduce an NdeI site at the 5'-end including the start codon and a BamHI site at the 3'-end immediately after the stop codon. For GFTpsB, the forward primer GFTpsBNdeI (SEQ ID NO:57) 5'-GCATGTTCCATATGTCGCTCAAGTTCTAGCAACGGTTTCC-3' (NdeI site in italics, start codon underlined) and the reverse primer GFTpsBBam (SEQ ID NO:58) 5'-CGCGGATCCTCAGATGGTAACAGGGTCTCTGAGCACTGC-3' (BamHI site in italics, stop codon underlined) were used. In the same way, the forward primer GFTpsDNdeI (SEQ ID NO:59) 5'-

GCATGTTCCATATGTCGTCTGGAGAAACATTCGTCC-3' and the reverse primer GFTpsDBam (SEQ ID NO:60) 5'-

CGCGGATCCTCAAATGGAACGTGGTCTCCTAG-3' were used for GFTpsD and the forward primer GFTpsENdel (SEQ ID NO:61) 5'-

GCATGTTCCATATGTCCTTTGGAAGTTTCAGCCTCTCCTG-3' and the reverse primer GFTpsEBam (SEQ ID NO:62) 5'-

CGCGGATCCTCATATCGGCACAGGATTAATAACAAAGAAGC-3' were used for GFTpsE.

[00106] The amplifications were performed using the Pfu DNA polymerase (Promega) in a final volume of 50 μ l containing 5 μ l of Pfu DNA polymerase 10X buffer, 200 μ M each dNTP, 0.4 μ M each forward and reverse primer, 2.9 units Pfu DNA polymerase and 5 μ l of 100-fold diluted cDNA (prepared as described above using the Marathon™ cDNA Amplification Kit (Clontech)). The thermal cycling conditions were as follows: 2 min at 95°C; 25 cycles of 30 sec at 95°C, 30 sec at 55°C and 4 min at 72°C; and 10 min at 72°C. The PCR product was purified on an agarose gel, eluted using the QIAquick® Gel Extraction Kit (Qiagen), digested with NdeI and BamHI and ligated into the similarly digested pET11a plasmid.

[00107] For construction of the GFTpsC-pET11a expression vector, two separated PCR were employed to generate the insert flanked with the NdeI and BamHI cohesive ends. A first PCR was performed in the same condition as described above, using the forward primer GFTpsCpETF1 (SEQ ID NO:63) 5'-TAATGGCACTTCAAGATTCAGAAGTTCCTC-3' and the reverse primer GFTpsCpETR1 (SEQ ID NO:64) 5'-

AAAAGGGAACAGGCTTCTCAAGCAATG-3' and a second PCR was performed using the forward primer GFTpsCpETF2 (shortened by AT at the 5'-end compared to GFTpsCpETF1) (SEQ ID NO:65) 5'-

ATGGCACTTCAAGATTCAGAAGTTCCTC-3' and the reverse primer GFTpsCpETR2 (extended by GATC at the 5'-end compared to GFTpsCpETR1) (SEQ ID NO:66) 5'-

GATCAAAAGGGAACAGGCTTCTCAAGCAATG-3'. The two PCR products were purified as described above, combined, denatured by 5 min boiling and

cooled 5 min on ice. The resulting cDNA was used directly for ligation into the pET11a plasmid.

[00108] Ligation products were initially transformed into JM109 *E. coli* cells and the constructs were verified by restriction digestion and DNA sequencing.

Sesquiterpene synthases expression.

[00109] For protein expression, the pET11a plasmids containing the sesquiterpene synthase cDNAs as well as the empty pET11a plasmid were transformed into the BL21(DE3) *E. coli* cells (Novagen). Single colonies were used to inoculate 5 ml LB medium. After 5 to 6 hours incubation at 37°C, the cultures were transferred to a 20°C incubator and left 1 h for equilibration. Expression of the protein was then induced by addition of 0.5 mM IPTG and the culture incubated over-night at 20°C.

[00110] The next day, the cells were collected by centrifugation, resuspended in 0.5 ml Extraction Buffer (50 mM MOPSO pH 7, 5 mM EDTA, 5 mM EDTA, 10% glycerol) and sonicated 3 times 30 s. The cell debris were sedimented by centrifugation 30 min at 18,000g and the supernatant containing the soluble proteins was recovered. The expression of the sesquiterpene synthases was evaluated by separation of the protein extract on a SDS-PAGE (SDS-polyacrylamid gel electrophoresis) and staining with coomassie blue and comparison to protein extract obtained from cells transformed with the empty plasmid.

[00111] A distinct band with the expected calculated molecular weight was observed for all constructs and the band was not present in the soluble proteins from *E. coli* transformed with the empty plasmid.

Example 4 Enzyme Function Assay

[00112] The enzymatic assays were performed in sealed glass tubes using 50 to 100 µl of protein extract in a final volume of Extraction Buffer supplemented with 15 mM MgCl₂ and 100 to 250 µM FPP (Sigma). The medium were overlaid with 1 ml pentane and the tubes incubated over-night at 30°C. The pentane phase, containing the sesquiterpenes, was recovered

and the medium extract with a second volume of pentane. The combined pentane fractions were concentrated under nitrogen and analyzed by Gas Chromatography on a Hewlett-Packard 6890 Series GC system using a 0.25 mm inner diameter by 30 m SPB-1 (Supelco) capillary column. The carrier gas was He at constant flow of 1.6 ml/min. Injection was done at a split ratio of 2:1 with the injector temperature set at 200°C and the oven programmed from 80°C (0 min hold) at 7.5°C/min to 200°C (0 min hold) followed by 20°C/min to 280°C (2 min hold). Detection was made with a flame ionization detector. Compound identification was based on retention time identity with authentic standards when available. For confirmation of the products identities, samples were analyzed by combined capillary GC-MS using a Hewlett-Packard 6890 GC-quadrupole mass selective detector system, equipped with a 0.25 mm inner diameter by 30 m SPB-1 (Supelco) capillary column. The oven was programmed from 80°C (0 min hold) to 280°C at 7.5°C at a constant flow of 1.5 ml/min He. The spectra were recorded at 70eV with an electron multiplier voltage of 2200V.

[00113] The enzyme activity of the different recombinant enzymes were evaluated in this assay using the soluble protein fraction and farnesyl-diphosphate as substrate. Sesquiterpene synthase activity was obtained for all clones tested and the product formed were characterized by retention time and GC-MS (Figure 7). The GFTpsB cDNA encoded a sesquiterpene synthase producing bicyclo-germacrene (Figure 3) as major product and at least 15 minor sesquiterpene olefins or oxygenated sesquiterpenes such as delta-cadinene (Figure 3) (byclo-elemene (Figure 3), resulting from heat rearrangement of bicyclo-germacrene was also observed in the GC trace). The GFTpsC cDNA encoded a multiple product forming sesquiterpene synthase with a major product being identified as cubebol (Figure 3). The enzyme also produced 3 other sesquiterpenes in a relative large proportion (-)- α -cubebene and 2 oxygenated sesquiterpenes, and in small amounts, at least 11 sesquiterpene olefins or oxygenated sesquiterpenes. GFTpsD encoded a sesquiterpene synthase that produces Valencene as a major product. Ten other minor peaks were also identified as sesquiterpene olefins

or alcohols. Among them, β -elemene is a heat degradation product of germacrene A. GFTpsE encoded a sesquiterpene synthase producing a complex mixture of sesquiterpene compounds with δ -cadinene (figure 3) being slightly the most abundant. Cubebol and Germacrene D (Figure 3) were also identified in the mixture of products formed by GFTpsE.

[00114] The isolated sesquiterpene synthases demonstrated multiple product forming properties in the experiments described. For example, the cubebol synthase and the δ -cadinene produce 3 or 5 products in relatively large proportion. The bicyclogermacrene synthase produced a major sesquiterpene and several secondary products in trace amounts.

We claim:

1. An isolated nucleic acid selected from
 - (a) a nucleic acid comprising the nucleotide sequence substantially as set out in SEQ ID NO:6 or SEQ ID NO:7;
 - (b) a nucleic acid encoding the polypeptide substantially set out in SEQ ID NO:1 or SEQ ID NO:2; and
 - (c) a nucleic acid that hybridizes to the nucleic acid of (a) or (b) under low stringency conditions, wherein the polypeptide encoded by said nucleic acid is a sesquiterpene synthase.
2. The isolated nucleic acid of claim 1, wherein the nucleic acid comprises the nucleotide sequence substantially as set out in SEQ ID NO:6 or SEQ ID NO:7.
3. The isolated nucleic acid of claim 2, wherein the nucleotide sequence is at least 85% identical to SEQ ID NO:6 or SEQ ID NO:7.
4. The isolated nucleic acid of claim 3, wherein the nucleotide sequence is at least 90% identical to SEQ ID NO:6 or SEQ ID NO:7.
5. The isolated nucleic acid of claim 4, wherein the nucleotide sequence is at least 95% identical to SEQ ID NO:6 or SEQ ID NO:7.
6. The isolated nucleic acid of claim 1, wherein the nucleic acid comprises the nucleotide sequence SEQ ID NO:6.
7. The isolated nucleic acid of claim 1, wherein the nucleic acid comprises the nucleotide sequence SEQ ID NO:7.

8. The isolated nucleic acid of claim 1, wherein the nucleic acid encodes the polypeptide substantially set out in SEQ ID NO:1 or SEQ ID NO:2.
9. The isolated nucleic acid of claim 8, wherein the polypeptide is at least 85% identical to SEQ ID NO:1 or SEQ ID NO:2.
10. The isolated nucleic acid of claim 9, wherein the polypeptide is at least 90% identical to SEQ ID NO:1 or SEQ ID NO:2.
11. The isolated nucleic acid of claim 10, wherein polypeptide is at least 95% identical to SEQ ID NO:1 or SEQ ID NO:2.
12. The isolated nucleic acid of claim 11, wherein the nucleic acid encodes the polypeptide SEQ ID NO:1 or SEQ ID NO:2.
13. A polypeptide encoded by the nucleic acid of claim 1.
14. The isolated nucleic acid of claim 1, wherein the nucleic acid hybridizes to the nucleic acid of (a) or (b) under moderate stringency conditions.
15. The isolated nucleic acid of claim 14, wherein the nucleic acid hybridizes to the nucleic acid of (a) or (b) under high stringency conditions.
16. The isolated nucleic acid of claim 1, wherein the nucleic acid is isolated from a citrus.
17. The isolated nucleic acid of claim 16, wherein said citrus is a grapefruit or an orange.
18. A vector comprising the nucleic acid of claim 1.

19. The vector of claim 18, wherein said vector is a viral vector or plasmid.
20. A host cell comprising the nucleic acid of claim 1.
21. An non-human organism modified to harbor the nucleic acid of claim 1.
22. The non-human organism of claim 21, wherein said non-human organism is modified using electroporation or particle-mediated gene transfer.
23. The non-human organism of claim 21, wherein said organism is a plant or microorganism.
24. A method of making a recombinant host cell comprising introducing the vector of claims 18 into a host cell.
25. A method of producing a polypeptide comprising culturing the host cell of claim 20 under conditions to produce said polypeptide.
26. The method of claim 25, wherein the host cell is chosen from bacterial cells, yeast cells, plant cells, and animal cells.
27. The method of claim 25, wherein the host cell is chosen from E. coli cells and microbial cells.
28. An isolated polypeptide comprising an amino acid sequence substantially as set out in SEQ ID NO:1 or SEQ ID NO:2.
29. The polypeptide of claim 28, wherein the amino acid sequence is at least 85% identical to SEQ ID NO:1 or SEQ ID NO:2.

30. The polypeptide of claim 29, wherein the amino acid sequence is at least 90% identical to SEQ ID NO:1 or SEQ ID NO:2.

31. The polypeptide of claim 30, wherein the amino acid sequence is at least 95% identical to SEQ ID NO:1 or SEQ ID NO:2.

32. A method of making at least one sesquiterpene synthase comprising

culturing a host modified to contain at least one nucleic acid sequence under conditions conducive to the production of said at least one sesquiterpene synthase

wherein said at least one nucleic acid is chosen from

(a) a nucleic acid comprising the nucleotide sequence substantially as set out in SEQ ID NO:6, SEQ ID NO:7, SEQ ID NO:8, SEQ ID NO:9, or SEQ ID NO:10;

(b) a nucleic acid encoding the polypeptide substantially set out in SEQ ID NO:6, SEQ ID NO:7, SEQ ID NO:8, SEQ ID NO:9, or SEQ ID NO:10; and

(c) a nucleic acid that hybridizes to the nucleic acid of (a) or (b) under low stringency conditions, wherein the polypeptide encoded by said nucleic acid is a sesquiterpene synthase.

33. The method of claim 32, wherein the nucleic acid comprises the nucleotide sequence substantially as set out in SEQ ID NO:6, SEQ ID NO:7, SEQ ID NO:8, SEQ ID NO:9, or SEQ ID NO:10.

34. The method of claim 32, wherein the nucleic acid comprises the nucleotide sequence SEQ ID NO:6, SEQ ID NO:7, SEQ ID NO:8, SEQ ID NO:9, or SEQ ID NO:10.

35. The method of claim 32, wherein the nucleic acid encodes the polypeptide substantially set out in SEQ ID NO:1, SEQ ID NO:2, SEQ ID NO:3, SEQ ID NO:9, or SEQ ID NO:10.

36. The method of claim 32, wherein the nucleic acid encodes the polypeptide SEQ ID NO:1, SEQ ID NO:2, SEQ ID NO:3, SEQ ID NO:9, or SEQ ID NO:10.

37. The method of claim 32, wherein said host is a plant or microorganism.

38. The method of claim 32, wherein said host is chosen from bacterial cells, yeast cells, plant cells, and animal cells.

39. A method of making at least one terpenoid comprising

A) contacting at least one acyclic pyrophosphate terpene precursor with at least one polypeptide encoded by a nucleic acid chosen from

(a) a nucleic acid comprising the nucleotide sequence substantially as set out in SEQ ID NO:6, SEQ ID NO:7, SEQ ID NO:8, SEQ ID NO:9, or SEQ ID NO:10;

(b) a nucleic acid encoding the polypeptide substantially set out in SEQ ID NO:6, SEQ ID NO:7, SEQ ID NO:8, SEQ ID NO:9, or SEQ ID NO:10; and

(c) a nucleic acid that hybridizes to the nucleic acid of (a) or (b) under low stringency conditions, wherein the polypeptide encoded by said nucleic acid is a sesquiterpene synthase.



B) isolating at least one terpenoid produced in A).

40. The method of claim 39, wherein said at least one terpenoid is chosen from sesquiterpenes.

41. The method of claim 39, wherein said at least one acyclic pyrophosphate terpene precursor is farnesyl-pyrophosphate.
42. The method of claim 41, wherein said at least one sesquiterpenes is chosen from bicylogermacrene, cubebol, valencene, α -cubebene, germacrene D and δ -cadine.
43. The method of claim 41, wherein said at least one sesquiterpenes is chosen from bicylogermacrene, cubebol, valencene and δ -cadine.
44. The method of claim 39, wherein the nucleic acid comprises the nucleotide sequence substantially as set out in SEQ ID NO:6, SEQ ID NO:7, SEQ ID NO:8, SEQ ID NO:9, or SEQ ID NO:10.
45. The method of claim 39, wherein the pH at the time of contacting is 7.
46. The method of claim 39, wherein the pH at the time of contacting is less than 7.
47. The method of claim 39, wherein said at least one terpenoid is isolated by at least one method chosen from extraction and distillation.
48. The method of claim 39, wherein the least one polypeptide is produced by culturing a host cell comprising the nucleic acid, wherein the host cell is chosen from bacterial cells, yeast cells, plant cells, and animal cells.
49. The method of claim 39, wherein the least one polypeptide is produced by culturing a host cell comprising the nucleic acid, wherein the host cell is chosen from

E. coli cells and microbial cells.

1/21

FIG. 1A**FIG. 1B**

2/21






FIG. 2

3/21





5/21

GFTpsA	10	DLGFPKKVPY	20	ARDRVVEYI	30	WMLLCVSYEP	40	NLATGRIFAS	KVVCIIISIT
GFTpsB		-----		-----		--IVGTYEFP		KMTLARKIMT	KTYTASTI
GFTpsC		-----		-----		---MGVYTFEP		KMTLARKIMT	KVILAMASIL

FIG. 5

6/21




FIG. 6A

7/21

GFTpsA
 GFTpsB
 GFTpsC
 GFTpsD1
 GFTpsD2
 GFTpsE

310 320 330 340 350 360 370 380 390 400
|.....|.....|.....|.....|.....|.....|.....|.....|.....|

GVSIEPNIATGRIEAFASKVMCIISLIDDIIDANGIEEIIITFAVT
 GTPVEEIKVILARKIMVKIITATSLIDDIIDANGIEEIIITFAVT
 GVAIEERIISARKIISKVITAMSIIDDIIDANGIEEIIITFAVT
 GTPVEEPOVATGCKIMVQINVIISLIDDIIDANGIEEIIITFAVT
 GTPVEEPOVATGCKIMVQINVIISLIDDIIDANGIEEIIITFAVT
 GVAIEEROISAPRIITIAKVISIIDDIIDANGIEEIIITFAVT

GFTpsA
 GFTpsB
 GFTpsC
 GFTpsD1
 GFTpsD2
 GFTpsE

410 420 430 440 450 460 470 480 490 500
|.....|.....|.....|.....|.....|.....|.....|.....|.....|

FTVQAKWPSGKVPIMDEIVYGLVSCIFMTANSTIGMCI
 YEEFAWCSGEGEIVDEIVYGLVSCIFMTANSTIGMCI
 YSVQAKWPSGKVPIMDEIVYGLVSCIFMTANSTIGMCI
 YSVQAKWPSGKVPIMDEIVYGLVSCIFMTANSTIGMCI
 YSVQAKWPSGKVPIMDEIVYGLVSCIFMTANSTIGMCI


GFTpsA
 GFTpsB
 GFTpsC
 GFTpsD1
 GFTpsD2
 GFTpsE

510 520 530 540 550 560 570
|.....|.....|.....|.....|.....|.....|



FTVQAKWPSGKVPIMDEIVYGLVSCIFMTANSTIGMCI
 YEEFAWCSGEGEIVDEIVYGLVSCIFMTANSTIGMCI
 YSVQAKWPSGKVPIMDEIVYGLVSCIFMTANSTIGMCI
 YSVQAKWPSGKVPIMDEIVYGLVSCIFMTANSTIGMCI
 YSVQAKWPSGKVPIMDEIVYGLVSCIFMTANSTIGMCI

FIG. 6B


8/21

**FIG. 7A**

9/21

**FIG. 7B**

10/21

**FIG. 7C**

11/21

GFTpsA

1	CAA	AAA	CTA	CAC	ATG	ATT	GAT	GCA	GCA	CAA	CGA	TTA	GGT	GTC	GCT	45
1	Q	K	L	H	M	I	D	A	A	Q	R	L	G	V	A	15
46	TAT	CAT	TTT	GAA	AAA	GAG	ATT	GAA	GAT	GAA	TTG	GGA	AAG	GTA	TCT	90
16	Y	H	F	E	K	E	I	E	D	E	L	G	K	V	S	30
91	CAT	GAT	CTT	GAC	AGT	GAT	GAT	CTA	TAC	GTT	GTT	TCT	CTT	CGT	TTT	135
31	H	D	L	D	S	D	D	L	Y	V	V	S	L	R	F	45
136	CGA	CTT	TTT	AGA	CAG	CAA	GGA	GTT	AAG	ATT	TCA	TGT	GAT	GTG	TTT	180
46	R	L	F	R	Q	Q	G	V	K	I	S	C	D	V	F	60
181	GAG	AAG	TTC	AAA	GAT	GAC	GAA	GGT	AAA	TTC	AAG	GAA	TCA	TTG	ATC	225
61	E	K	F	K	D	D	E	G	K	F	K	E	S	L	I	75
226	AAC	GAT	ATA	CGA	GGC	ATG	TCG	AGT	TTG	TAC	GAG	GCA	GCA	TAC	CTA	270
76	N	D	I	R	G	M	S	S	L	Y	E	A	A	Y	L	90
271	GCA	ATT	CGG	GGG	GAA	GAC	ATT	TTA	GAT	GAA	GCC	ATT	GTT	TTC	ACT	315
91	A	I	R	G	E	D	I	L	D	E	A	I	V	F	T	105
316	ACC	ACT	CAC	CTT	AAG	TCA	GTA	ATA	TCT	GTA	TCT	GAT	CAT	TCT	CAT	360
106	T	T	H	L	K	S	V	I	S	V	S	D	H	S	H	120
361	GTA	AAC	TCT	GAT	CTT	GCT	GAA	CAA	ATA	CGT	CAT	TCT	CTG	CAA	ATT	405
121	V	N	S	D	L	A	E	Q	I	R	H	S	L	Q	I	135
406	CCT	CTC	CGT	AAA	GCC	GCA	GCA	AGG	TTA	GAG	GCA	AGG	TAT	TTT	TTG	450
136	P	L	R	K	A	A	A	R	L	E	A	R	Y	F	L	150
451	GAT	ATC	TAT	TCA	AGG	GAT	GAT	TTG	CAT	GAT	GAA	ACT	TTG	CTC	AAG	495
151	D	I	Y	S	R	D	D	L	H	D	E	T	L	L	K	165
496	TTT	GCA	AAG	TTA	GAC	TTT	AAT	ATA	TTA	CAA	GCA	GCA	CAC	AAG	AAG	540
166	F	A	K	L	D	F	N	I	L	Q	A	A	H	K	K	180
541	GAA	GCA	AGT	ATC	ATG	ACC	AGG	TGG	TGG	AAC	GAT	TTA	GGC	TTC	CCT	585
181	E	A	S	I	M	T	R	W	W	N	D	L	G	F	P	195
586	AAA	AAG	GTG	CCT	TAT	GCA	AGA	GAT	AGA	GTA	GTA	GAG	ACA	TAT	ATT	630
196	K	K	V	P	Y	A	R	D	R	V	V	E	T	Y	I	210
631	TGG	ATG	TTG	CTG	GGA	GTG	TCC	TAT	GAG	CCC	AAT	TTG	GCA	TTT	GGT	675
211	W	M	L	L	G	V	S	Y	E	P	N	L	A	F	G	225
676	AGA	ATT	TTT	GCA	TCC	AAA	GTG	GTG	TGC	ATA	ATA	TCC	ATA	ATA	GAC	720
226	R	I	F	A	S	K	V	V	C	I	I	S	I	I	D	240
721	GAC	ACA	TTT	GAT	GCT	TAC	GGT	ACT	TTT	GAA	GAG	CTC	ACA	CTT	TTT	765
241	D	T	F	D	A	Y	G	T	F	E	E	L	T	L	F	255
766	ACT	GAA	GCA	GTC	ACA											780
256	T	E	A	V	T											

FIG. 8(a)

12/21

GFTpsB

1	ATG	TCC	GCT	CAA	GTT	CTA	GCA	ACG	GTT	TCC	AGT	TCG	ACA	GAA	AAA	45
1	M	S	A	Q	V	L	A	T	V	S	S	S	T	E	K	15
46	ACT	GTT	CGT	CCC	ATT	GCT	GGT	TTC	CAT	CCT	AAC	TTA	TGG	GGA	GAC	90
16	T	V	R	P	I	A	G	F	H	P	N	L	W	G	D	30
91	TAT	TTC	CTG	ACC	CTC	GCT	TCT	GAT	TGC	AAG	ACA	GAT	GAT	ACT	ACG	135
31	Y	F	L	T	L	A	S	D	C	K	T	D	D	T	T	45
136	CAC	CAA	GAG	GAA	TAC	GAA	GCG	CTG	AAG	CAA	GAA	GTC	AGA	AGC	ATG	180
46	H	Q	E	E	Y	E	A	L	K	Q	E	V	R	S	M	60
181	ATA	ACG	GCT	ACG	GCA	GAT	ACA	CCT	GCC	CAG	AAG	TTG	CAA	TTG	GTT	225
61	I	T	A	T	A	D	T	P	A	Q	K	L	Q	L	V	75
226	GAT	GCA	GTC	CAA	CGA	TTG	GGT	GTG	GCC	TAT	CAC	TTC	GAA	CAG	GAG	270
76	D	A	V	Q	R	L	G	V	A	Y	H	F	E	Q	E	90
271	ATA	GAA	GAT	GCA	ATG	GAA	AAG	ATT	TAT	CAC	GAT	GAC	TTT	GAT	AAT	315
91	I	E	D	A	M	E	K	I	Y	H	D	D	F	D	N	105
316	AAC	GAT	GAT	GTC	GAT	CTC	TAC	ACT	GTT	TCT	CTT	CGT	TTT	CGA	CTG	360
106	N	D	D	V	D	L	Y	T	V	S	L	R	F	R	L	120
361	CTT	AGG	CAG	CAA	GGA	TTT	AAG	GTT	CCG	TGT	GAT	GTG	TTC	GCG	AAG	405
121	L	R	Q	Q	G	F	K	V	P	C	D	V	F	A	K	135
406	TTC	AAA	GAT	GAT	GAA	GGT	AAA	TTC	AAG	GCA	TCA	TTG	GTG	CGG	GAT	450
136	F	K	D	D	E	G	K	F	K	A	S	L	V	R	D	150
451	GTT	CAT	GGC	ATT	CTA	AGT	TTG	TAT	GAG	GCA	GGA	CAC	TTG	GCC	ATT	495
151	V	H	G	I	L	S	L	Y	E	A	G	H	L	A	I	165
496	CGC	GGA	GAA	GGG	ATA	TTA	GAT	GAA	GCC	ATT	GCT	TTC	ACT	AGA	ACT	540
166	R	G	E	G	I	L	D	E	A	I	A	F	T	R	T	180
541	CAC	CTT	CAG	TCA	ATG	GTA	TCT	CAG	GAT	GTA	TGC	CCT	AAT	AAT	CTT	585
181	H	L	Q	S	M	V	S	Q	D	V	C	P	N	N	L	195
586	GCT	GAA	CAA	ATT	AAT	CAT	ACT	CTC	GAC	TGT	CCT	CTC	CGC	AGA	GCC	630
196	A	E	Q	I	N	H	T	L	D	C	P	L	R	R	A	210
631	CTT	CCA	AGA	CTC	GAG	ACA	AGA	TTT	TTC	TTG	TCG	GTC	TAT	CCA	AGA	675
211	L	P	R	V	E	T	R	F	F	L	S	V	Y	P	R	225
676	GAT	GAT	AAA	CAC	GAT	AAA	ACT	TTG	TTA	AAG	TTT	TCA	AAG	TTA	GAC	720
226	D	D	K	H	D	K	T	L	L	K	F	S	K	L	D	240
721	TTT	AAC	CTT	GTG	CAA	AGA	ATA	CAT	CAG	AAG	GAA	TTA	AGT	GCC	ATC	765
241	F	N	L	V	Q	R	I	H	Q	K	E	L	S	A	I	255
766	ACA	CGG	TGG	TGG	AAA	GAT	TTA	GAC	TTC	ACT	ACA	AAG	CTA	CCT	TAT	810
256	T	R	W	W	K	D	L	D	F	T	T	K	L	P	Y	270

FIG. 8(b)-1

13/21

811	GCA AGA GAC AGA ATC GTA GAG TTG TAT TTT TGG ATT GTA GGG ACG	855
271	A R D R I V E L Y F W I V G T	285
856	TAT TTT GAA CCA AAG TAC ACT TTA GCA AGA AAA ATA ATG ACC AAA	900
286	Y F E P K Y T L A R K I M T K	300
901	ACA ATT TAC ACG GCA TCT ATC ATA GAT GAC ACT TTC GAC GCT TAT	945
301	T I Y T A S I I D D T F D A Y	315
946	GGT TTC TTT GAA GAG CTC AAA CTC TTT GCA GAA GCA GTC CAG AGG	990
316	G F F E E L K L F A E A V Q R	330
991	TGG GAC ATT GGA GCC ATG GAT ATA CTT CCA GAA TAC ATG AAA GTG	1035
331	W D I G A M D I L P E Y M K V	345
1036	CTT TAT AAG GCC CTT TTA GAT ACT TTC AAT GAA ATT GAG CAA GAC	1080
346	L Y K A L L D T F N E I E Q D	360
1081	TTG GCC AAG GAA GGA AGA TCG TCC TAC TTA CCT TAT GGC AAA GAA	1125
361	L A K E G R S S Y L P Y G K E	375
1126	AAG ATG CAA GAG CTT GTT CAA ATG TAC TTT GTT CAA GCC AAG TGG	1170
376	K M Q E L V Q M Y F V Q A K W	390
1171	TTC CGT GAA GGT TAT GTT CCG ACA TGG GAC GAA TAT TAT CCG GTT	1215
391	F S E G Y V P T W D E Y Y P V	405
1216	GGA CTT GTA AGT TGC GGC TAC TTC ATG CTT GCG ACA AAC TCC TTC	1260
406	G L V S C G Y F M L A T N S F	420
1261	CTT GGC ATG TGT GAT GTT GCA AAC GAG GAA GCT TTT GAA TGG ATA	1305
421	L G M C D V A N E E A F E W I	435
1306	TCC AAG GAC CCT AAG ATT TCA ACA GCG TCA TCA GTT ATC TGC AGA	1350
436	S K D P K I S T A S S V I C R	450
1351	CTT AGG AAT GAC ATT GTT TCC CAC CAG TTT GAA CAG AAG AGA GGA	1395
451	L R N D I V S H Q F E Q K R G	465
1396	CAT ATT GCC TCA GGA TTT GAA TGC TAC ATT AAG CAG TAT GGT GTT	1440
466	H I A S G F E C Y I K Q Y G V	480
1441	TCA GAA GAA GAG GTA GTT ACA GTT TTT ACT GAA GAA GTT GAG AAT	1485
481	S E E E V V T V F T E E V E N	495
1486	GCA TGG AAA GAT ATG AAT GAG GAA TTC CTG AAA CCA ACT GCT TTT	1530
496	A W K D M N E E F L K P T A F	510
1531	CCT GTG GCT TTG ATT GAG AGA CCT TTC AAT ATC GCA CGT GTG ATT	1575
511	P V A L I E R P F N I A R V I	525
1576	GAA TTT CTA AAC AAG AAG GGT GAT TGG TAC ACT CAT TCT CAT GCG	1620
526	E F L N K K G D W Y T H S H A	540
1621	ATT AAA GAC CAG ATT GCC GCA GTG CTC AGA GAC CCT GTT ACC ATC	1665
541	I K D Q I A A V L R D P V T I	555

FIG. 8(b)-2

14/21

GFTpsC

1	ATG	GCA	CTT	CAA	GAT	TCA	GAA	GTT	CCT	TCT	TCC	ATT	CTG	AAT	GCT	45
1	M	A	L	Q	D	S	E	V	P	S	S	I	L	N	A	15
46	ACA	GCC	GGC	AAC	CGT	CCC	ACA	GCT	AGT	TAT	CAT	CCC	ACC	CTC	TGG	90
16	T	A	G	N	R	P	T	A	S	Y	H	P	T	L	W	30
91	GGG	GGA	AAA	TTC	CTT	GAC	TAT	TCT	TCT	GTT	GAC	GAC	TCT	GAG	GCA	135
31	G	G	K	F	L	D	Y	S	S	V	D	D	S	E	A	45
136	ATG	GAT	GCC	ACA	ATT	GAT	CAA	GAC	GAA	TTT	GAA	GCA	CTT	AAG	CAA	180
46	M	D	A	T	I	D	Q	D	E	F	E	A	L	K	Q	60
181	AAA	ATA	AAG	AAC	ATG	TTA	ATC	TCA	CCA	ACC	GAT	AAG	TCT	TTT	CAA	225
61	K	I	K	N	M	L	I	S	P	T	D	K	S	F	Q	75
226	AAA	TTG	AAC	TTG	ATT	GAT	GCC	GTC	CAA	CGC	TTA	GGA	GTG	GCT	TAC	270
76	K	L	N	L	I	D	A	V	Q	R	L	G	V	A	Y	90
271	CAT	TTT	GAG	AGG	GAG	ATA	GAA	GAT	GAA	CTA	GAA	AAA	CTA	TCT	CCT	315
91	H	F	E	R	E	I	E	D	E	L	E	K	L	S	P	105
316	GAT	GAG	TAT	GAT	GGC	AAC	GAT	GTA	CAC	TCC	GTT	GCT	CTT	CGA	TTT	360
106	D	E	Y	D	G	N	D	V	H	S	V	A	L	R	F	120
361	CGG	TTA	CTC	AGA	CAA	CAA	GGA	TAT	CGC	ATA	TCA	TGC	GAT	ATT	TTT	405
121	R	L	L	R	Q	Q	G	Y	R	I	S	C	D	I	F	135
406	GGC	GGT	TTC	AAA	GAT	GAT	CGA	GGA	AAG	TTC	AAG	GTA	TCC	TTA	ATT	450
136	G	G	F	K	D	D	R	G	K	F	K	V	S	L	I	150
451	AAT	GAT	GTG	ACC	GGC	ATG	CTA	AGT	TTG	TAT	GAG	GCT	GCA	CAT	CTT	495
151	N	D	V	T	G	M	L	S	L	Y	E	A	A	H	L	165
496	CGC	ATT	CGC	GGG	GAA	GAT	ATC	CTG	GAT	GAA	GCC	CTA	GCT	TTC	ACT	540
166	R	I	R	G	E	D	I	L	D	E	A	L	A	F	T	180
541	ACT	TCT	CAC	CTG	GAA	TCA	ATG	GTT	ACT	CAA	GTA	AGC	CCT	CAG	CTT	585
181	T	S	H	L	E	S	M	V	T	Q	V	S	P	Q	L	195
586	TCT	GAT	GAA	ATA	CTT	CAT	GCC	TTG	AAT	AGG	CCA	ATC	CGC	AGA	GGC	630
196	S	D	E	I	L	H	A	L	N	R	P	I	R	R	G	210
631	TTA	CCA	AGG	CTG	GAG	GCA	GTC	TAT	TAC	ATC	GAT	CTC	TAC	TCA	CGA	675
211	L	P	R	L	E	A	V	Y	Y	I	D	L	Y	S	R	225
676	GAT	GAT	TCA	AAG	GAT	AAA	GCA	ATA	TTA	CTA	AAG	TTT	GCA	AAA	CTA	720
226	D	D	S	K	D	K	A	I	L	L	K	F	A	K	L	240
721	GAT	TTT	TGC	ATG	CTT	CAA	GTA	ATT	CAC	CGT	AAG	GAG	TTA	AGT	ATC	765
241	D	F	C	M	L	Q	V	I	H	R	K	E	L	S	I	255
766	ATC	ACA	GAG	TGG	TGG	AAA	AAT	TTA	GAT	GTT	GAA	ATA	AAT	CTC	CCA	810
256	I	T	E	W	W	K	N	L	D	V	E	I	N	L	P	270

FIG. 8(c)-1

15/21

811	TAT	GCT	AGA	AAC	AGA	GTT	GTA	GAA	TGC	TAT	TTT	TGG	GCA	ATG	GGA	855
271	Y	A	R	N	R	V	V	E	C	Y	F	W	A	M	G	285
856	GTG	TAT	TTT	GAG	CCT	CGA	TAC	TCC	TTT	GCA	AGA	AAG	ATA	TTG	TCC	900
286	V	Y	F	E	P	R	Y	S	F	A	R	K	I	L	S	300
901	AAA	GTA	ATT	GCA	ATG	GCA	TCC	ATT	TTA	GAT	GAT	ACC	TAC	GAC	GCC	945
301	K	V	I	A	M	A	S	I	L	D	D	T	Y	D	A	315
946	TAT	GGC	ACA	CTT	GAA	GAA	CTT	GAG	CTC	TTT	ACA	AAT	GCT	ATC	AAA	990
316	Y	G	T	L	E	E	L	E	L	F	T	N	A	I	K	330
991	AGG	TGG	GAT	ATT	AGC	AAC	ATA	GAT	GTA	CTT	CCG	AAG	TAC	ATG	AAA	1035
331	R	W	D	I	S	N	I	D	V	L	P	K	Y	M	K	345
1036	CTG	ATT	TAT	CAA	GGA	CTC	TTG	GAT	GTT	TTT	GGT	GAA	GCT	GAG	GAG	1080
346	L	I	Y	Q	G	L	L	D	V	F	G	E	A	E	E	360
1081	GAA	ATC	TCA	AAG	GAA	GGA	CAG	ACA	TAT	TGC	ATG	TCA	TAT	GTC	ATA	1125
361	E	I	S	K	E	G	Q	T	Y	C	M	S	Y	V	I	375
1126	CAA	GCG	GTG	AAG	AAA	GTA	GTC	CAA	GCC	TAC	TTT	GAG	GAA	GCC	AAG	1170
376	Q	A	V	K	K	V	V	Q	A	Y	F	E	E	A	K	390
1171	TGG	TGC	AGT	GAA	GGT	TAT	TTT	CCA	AAA	GTG	GAG	GAG	TAT	ATG	CAA	1215
391	W	C	S	E	G	Y	F	P	K	V	E	E	Y	M	Q	405
1216	GTT	TCA	CTT	GTG	ACA	ACT	TGC	TAT	CAT	ATG	CTG	GCA	ACG	GCT	TCT	1260
406	V	S	L	V	T	T	C	Y	H	M	L	A	T	A	S	420
1261	TTT	CTT	GGC	ATG	GGA	AAG	ATT	GCT	GAT	AAG	CAG	GCC	TTT	GAA	TGG	1305
421	F	L	G	M	G	K	I	A	D	K	Q	A	F	E	W	435
1306	ATC	TCC	AAT	TAC	CCT	AAA	ACT	GTG	AAA	GCC	TCC	CAA	GTT	ATT	TGC	1350
436	I	S	N	Y	P	K	T	V	K	A	S	Q	V	I	C	450
1351	AGA	CTT	ATG	GAT	GAT	ATA	GTG	TCT	CAC	GAG	TTT	GAA	CAA	AAA	AGA	1395
451	R	L	M	D	D	I	V	S	H	E	F	E	Q	K	R	465
1396	AAG	CAT	GTT	GCC	TCG	GGT	ATT	GAA	TGT	TAC	ATG	AAG	CAG	CAT	GGC	1440
466	K	H	V	A	S	G	I	E	C	Y	M	K	Q	H	G	480
1441	GTC	TCT	GAT	GAA	GAG	GTA	ATT	AAA	GTA	TTC	CGC	AAA	CAA	ATA	TCA	1485
481	V	S	D	E	E	V	I	K	V	F	R	K	Q	I	S	495
1486	AAT	GGA	TGG	AAA	GAT	GTA	AAT	GAA	GGA	TTC	ATG	AAG	CCA	ACA	GAA	1530
496	N	G	W	K	D	V	N	E	G	F	M	K	P	T	E	510
1531	GTG	GCA	ATG	CCT	CTC	CTT	GAG	CGC	ATT	CTC	AAT	CTT	GCA	CGA	GTG	1575
511	V	A	M	P	L	L	E	R	I	L	N	L	A	R	V	525
1576	ATA	GAT	GTT	ATT	TAC	AAG	GAT	GAT	GAT	GGC	TAC	ACC	AAC	TCT	TAT	1620
526	I	D	V	I	Y	K	D	D	D	G	Y	T	N	S	Y	540
1621	GTG	ATC	AAA	GAC	TAC	ATC	GCC	ACA	TTG	CTT	GAG	AAG	CCT	GTT	CCC	1665
541	V	I	K	D	Y	I	A	T	L	L	E	K	P	V	P	555
1666	TTT	TGA														
556	F	*														

FIG. 8(c)-2

16/21

GFTpsD1

1	ATG	TCG	TCT	GGA	GAA	ACA	TTT	CGT	CGT	ACT	GCA	GAT	TTC	CAT	CCT	45
1	M	S	S	G	E	T	F	R	P	T	A	D	F	H	P	15
46	AGT	TTA	TGG	AGA	AAC	CAT	TTC	CTC	AAA	GGT	GCT	TCT	GAT	TTC	AAG	90
16	S	L	W	R	N	H	F	L	K	G	A	S	D	F	K	30
91	ACA	GTT	GAT	CAT	ACT	GCA	ACT	CAA	GAA	CGA	CAC	GAG	GCA	CTG	AAA	135
31	T	V	D	H	T	A	T	Q	E	R	H	E	A	L	K	45
136	GAA	GAG	GTA	AGG	AGA	ATG	ATA	ACA	GAT	GCT	GAA	GAT	AAG	CCT	GTT	180
46	E	E	V	R	R	M	I	T	D	A	E	D	K	P	V	60
181	CAG	AAG	TTA	CGC	TTG	ATT	GAT	GAA	GTA	CAA	CGC	CTG	GGG	GTG	GCT	225
61	Q	K	L	R	L	I	D	E	V	Q	R	L	G	V	A	75
226	TAT	CAC	TTT	GAG	AAA	GAA	ATA	GAA	GAT	GCA	ATA	CAA	AAA	TTA	TGT	270
76	Y	H	F	E	K	E	I	E	D	A	I	Q	K	L	C	90
271	CCA	ATC	TAT	ATT	GAC	AGT	AAT	AGA	GCT	GAT	CTC	CAC	ACC	GTT	TCC	315
91	P	I	Y	I	D	S	N	R	A	D	L	H	T	V	S	105
316	CTT	CAT	TTT	CGA	TTG	CTT	AGG	CAG	CAA	GGA	ATC	AAG	ATT	TCA	TGT	360
106	L	H	F	R	L	L	R	Q	Q	G	I	K	I	S	C	120
361	GAT	GTG	TTT	GAG	AAG	TTC	AAA	GAT	GAT	GAG	GGT	AGA	TTC	AAG	TCA	405
121	D	V	F	E	K	F	K	D	D	E	G	R	F	K	S	135
406	TCG	TTG	ATA	AAC	GAT	GTT	CAA	GGG	ATG	TTA	AGT	TTG	TAC	GAG	GCA	450
136	S	L	I	N	D	V	Q	G	M	L	S	L	Y	E	A	150
451	GCA	TAC	ATG	GCA	GTT	CGC	GGA	GAA	CAT	ATA	TTA	GAT	GAA	GCC	ATT	495
151	A	Y	M	A	V	R	G	E	H	I	L	D	E	A	I	165
496	GCT	TTC	ACT	ACC	ACT	CAC	CTG	AAG	TCA	TTG	GTA	GCT	CAG	GAT	CAT	540
166	A	F	T	T	T	H	L	K	S	L	V	A	Q	D	H	180
541	GTA	ACC	CCT	AAG	CTT	GCG	GAA	CAG	ATA	AAT	CAT	GCT	TTA	TAC	CGT	585
181	V	T	P	K	L	A	E	Q	I	N	H	A	L	Y	R	195
586	CCT	CTT	CGT	AAA	ACC	CTA	CCA	AGA	TTA	GAG	GCG	AGG	TAT	TTT	ATG	630
196	P	L	R	K	T	L	P	R	L	E	A	R	Y	F	M	210
631	TCC	ATG	ATC	AAT	TCA	ACA	AGT	GAT	CAT	TTA	TAC	AAT	AAA	ACT	CTG	675
211	S	M	I	N	S	T	S	D	H	L	Y	N	K	T	L	225
676	CTG	AAT	TTT	GCA	AAG	TTA	GAT	TTT	AAC	ATA	TTG	CTA	GAG	CTG	CAC	720
226	L	N	F	A	K	L	D	F	N	I	L	L	E	L	H	240
721	AAG	GAG	GAA	CTC	AAT	GAA	TTA	ACA	AAG	TGG	TGG	AAA	GAT	TTA	GAC	765
241	K	E	E	L	N	E	L	T	K	W	W	K	D	L	D	255
766	TTC	ACT	ACA	AAA	CTA	CCT	TAT	GCA	AGA	GAC	AGA	TTA	GTG	GAG	TTA	810
256	F	T	T	K	L	P	Y	A	R	D	R	L	V	E	L	270

FIG. 8(d)-1

17/21

811 271	TAT TTT TGG GAT TTA GGG ACA TAC TTC GAG CCT	
	Y F W D L G T Y F E P	
856 286	GGG AGA AAG ATA ATG ACC CAA TTA AAT TAC ATA TTA TCC ATC ATA	900 300
	G R K I M T Q L N Y I L S I I	
901 301	GAT GAT ACT TAT GAT GCG TAT GGT ACA CTT GAA GAA CTC AGC CTC	945 315
	D D T Y D A Y G T L E E L S L	
946 316	TTT ACT GAA GCA GTT CAA AGA TGG AAT ATT GAG GCC GTA GAT ATG	990 330
	F T E A V Q R W N I E A V D M	
991 331	CTT CCA GAA TAC ATG AAA TTG ATT TAC AGG ACA CTC TTA GAT GCT	1035 345
	L P E Y M K L I Y R T L L D A	
1036 346	TTT AAT GAA ATT GAG GAA GAT ATG GCC AAG CAA GGA AGA TCA CAC	1080 360
	F N E I E E D M A K Q G R S H	
1081 361	TGC GTA CGT TAT GCA AAA GAG GAG AAT CAA AAA GTA ATT GGA GCA	1125 375
	C V R Y A K E E N Q K V I G A	
1126 376	TAC TCT GTT CAA GCC AAA TGG TTC AGT GAA GGT TAC GTT CCA ACA	1170 390
	Y S V Q A K W F S E G Y V P T	
1171 391	ATT GAG GAG TAT ATG CCT ATT GCA CTA ACA AGT TGT GCT TAC ACA	1215 405
	I E E Y M P I A L T S C A Y T	
1216 406	TTC GTC ATA ACA AAT TCC TTC CTT GGC ATG GGT GAT TTT GCA ACT	1260 420
	F V I T N S F L G M G D F A T	
1261 421	AAA GAG GTT TTT GAA TGG ATC TCC AAT AAC CCT AAG GTT GTA AAA	1305 435
	K E V F E W I S N N P K V V K	
1306 436	GCA GCA TCA GTT ATC TGC AGA CTC ATG GAT GAC ATG CAA GGT CAT	1350 450
	A A S V I C R L M D D M Q G H	
1351 451	GAG TTT GAG CAG AAG AGA GGA CAT GTT GCG TCA GCT ATT GAA TGT	1395 465
	E F E Q K R G H V A S A I E C	
1396 466	TAC ACG AAG CAG CAT GGT GTC TCT AAG GAA GAG GCA ATT AAA ATG	1440 480
	Y T K Q H G V S K E E A I K M	
1441 481	TTT GAA GAA GAA GTT GCA AAT GCA TGG AAA GAT ATT AAC GAG GAG	1485 495
	F E E E V A N A W K D I N E E	
1486 496	TTG ATG ATG AAG CCA ACC GTC GTT GCC CGA CCA CTG CTC GGG ACG	1530 510
	L M M K P T V V A R P L L G T	
1531 511	ATT CTT AAT CTT GCT CGT GCA ATT GAT TTT ATT TAC AAA GAG GAC	1575 525
	I L N L A R A I D F I Y K E D	
1576 526	GAC GGC TAT ACG CAT TCT TAC CTA ATT AAA GAT CAA ATT GCT TCT	1620 540
	D G Y T H S Y L I K D Q I A S	
1621 541	GTG CTA GGA GAC CAC GTT CCA TTT TGA	1647
	V L G D H V P F *	

FIG. 8(d)-2

18/21

GFTpsD2

1	ATG	TCG	TCT	GGA	GAA	ACA	TTT	CGT	CCT	ACT	GCA	GAT	TTC	CAT	CCT	45
1	M	S	S	G	E	T	F	R	P	T	A	D	F	H	P	15
46	AGT	TTA	TGG	AGA	AAC	CAT	TTC	CTC	AAA	GGT	GCT	TCT	GAT	TTC	AAG	90
16	S	L	W	R	N	H	F	L	K	G	A	S	D	F	K	30
91	ACA	GTT	GAT	CAT	ACT	GCA	ACT	CAA	GAA	CGA	CAC	GAG	GCA	CTG	AAA	135
31	T	V	D	H	T	A	T	Q	E	R	H	E	A	L	K	45
136	GAA	GAG	GTA	AGG	AGA	ATG	ATA	ACA	GAT	GCT	GAA	GAT	AAG	CCT	GTT	180
46	E	E	V	R	R	M	I	T	D	A	E	D	K	P	V	60
181	CAG	AAG	TTA	CGC	TTG	ATT	GAT	GAA	GTA	CAA	CGC	CTG	GGG	GTG	GCT	225
61	Q	K	L	R	L	I	D	E	V	Q	R	L	G	V	A	75
226	TAT	CAC	TTT	GAG	AAA	GAA	ATA	GAA	GAT	GCA	ATA	CAA	AAA	TTA	TGT	270
76	Y	H	F	E	K	E	I	E	D	A	I	Q	K	L	C	90
271	CCA	AAC	TAT	ATT	CAC	AGT	AAT	AGC	CCT	GAT	CTT	CAC	ACC	GTT	TCT	315
91	P	N	Y	I	H	S	N	S	P	D	L	H	T	V	S	105
316	CTT	CAT	TTT	CGA	TTG	CTT	AGG	CAG	CAA	GGA	ATC	AAG	ATT	TCA	TGT	360
106	L	H	F	R	L	L	R	Q	Q	G	I	K	I	S	C	120
361	GAT	GTG	TTT	GAG	AAG	TTC	AAA	GAT	GAT	GAG	GGT	AGA	TTC	AAG	TCA	405
121	D	V	F	E	K	F	K	D	D	E	G	R	F	K	S	135
406	TCG	TTG	ATA	AAC	GAT	GTT	CAA	GGG	ATG	TTA	AGT	TTG	TAC	GAG	GCA	450
136	S	L	I	N	D	V	Q	G	M	L	S	L	Y	E	A	150
451	GCA	TAC	ATG	GCA	GTT	CGC	GGA	GAA	CAT	ATA	TTA	GAT	GAA	GCC	ATT	495
151	A	Y	M	A	V	R	G	E	H	I	L	D	E	A	I	165
496	GCT	TTC	ACT	ACC	ACT	CAC	CTG	AAG	TCA	TTG	GTA	GCT	CAG	GAT	CAT	540
166	A	F	T	T	T	H	L	K	S	L	V	A	Q	D	H	180
541	GTA	ACC	CCT	AAG	CTT	GCG	GAA	CAG	ATA	AAT	CAT	GCT	TTA	TAC	CGT	585
181	V	T	P	K	L	A	E	Q	I	N	H	A	L	Y	R	195
586	CCT	CTT	CGT	AAA	ACC	CTA	CCA	AGA	TTA	GAG	GCG	AGG	TAT	TTT	ATG	630
196	P	L	R	K	T	L	P	R	L	E	A	R	Y	F	M	210
631	TCC	ATG	ATC	AAT	TCA	ACA	AGT	GAT	CAT	TTA	TAC	AAT	AAA	ACT	CTG	675
211	S	M	I	N	S	T	S	D	H	L	Y	N	K	T	L	225
676	CTG	AAT	TTT	GCA	AAG	TTA	GAT	TTT	AAC	ATA	TTG	CTA	GAG	CTG	CAC	720
226	L	N	F	A	K	L	D	F	N	I	L	L	E	L	H	240
721	AAG	GAG	GAA	CTC	AAT	GAA	TTA	ACA	AAG	TGG	TGG	AAA	GAT	TTA	GAC	765
241	K	E	E	L	N	E	L	T	K	W	W	K	D	L	D	255
766	TTC	ACT	ACA	AAA	CTA	CCT	TAT	GCA	AGA	GAC	AGA	TTA	GTG	GAG	TTA	810
256	F	T	T	K	L	P	Y	A	R	D	R	L	V	E	L	270

FIG. 8(e)-1

19/21

811	TAT	TTT	TGG	GAT	TTA	GGG	ACA	TAC	TTC	GAG	CCT	CAA	TAT	GCA	TTT	855
271	Y	F	W	D	L	G	T	Y	F	E	P	Q	Y	A	F	285
856	GGG	AGA	AAG	ATA	ATG	ACC	CAA	TTA	AAT	TAC	ATA	TTA	TCC	ATC	ATA	900
286	G	R	K	I	M	T	Q	L	N	Y	I	L	S	I	I	300
901	GAT	GAT	ACT	TAT	GAT	GCG	TAT	GGT	ACA	CTT	GAA	GAA	CTC	AGC	CTC	945
301	D	D	T	Y	D	A	Y	G	T	L	E	E	L	S	L	315
946	TTT	ACT	GAA	GCA	GTT	CAA	AGA	TGG	AAT	ATT	GAG	GCC	GTA	GAT	ATG	990
316	F	T	E	A	V	Q	R	W	N	I	E	A	V	D	M	330
991	CTT	CCA	GAA	TAC	ATG	AAA	TTG	ATT	TAC	AGG	ACA	CTC	TTA	GAT	GCT	1035
331	L	P	E	Y	M	K	L	I	Y	R	T	L	L	D	A	345
1036	TTT	AAT	GAA	ATT	GAG	GAA	GAT	ATG	GCC	AAG	CAA	GGA	AGA	TCA	CAC	1080
346	F	N	E	I	E	E	D	M	A	K	Q	G	R	S	H	360
1081	TGC	GTA	CGT	TAT	GCA	AAA	GAG	GAG	AAT	CAA	AAA	GTA	ATT	GGA	GCA	1125
361	C	V	R	Y	A	K	E	E	N	Q	K	V	I	G	A	375
1126	TAC	TCCT	GTT	CAA	GCC	AAA	TGG	TTC	AGT	GAA	GGT	TAC	GTT	CCA	ACA	1170
376	Y	S	V	Q	A	K	W	F	S	E	G	Y	V	P	T	390
1171	ATT	GAG	GAG	TAT	ATG	CCT	ATT	GCA	CTA	ACA	AGT	TGT	GCT	TAC	ACA	1215
391	I	E	E	Y	M	P	I	A	L	T	S	C	A	Y	T	405
1216	TTC	GTC	ATA	ACA	AAT	TCC	TTC	CTT	GGC	ATG	GGT	GAT	TTT	GCA	ACT	1260
406	F	V	I	T	N	S	F	L	G	M	G	D	F	A	T	420
1261	AAA	GAG	GTT	TTT	GAA	TGG	ATC	TCC	AAT	AAC	CCT	AAG	GTT	GTA	AAA	1305
421	K	E	V	F	E	W	I	S	N	N	P	K	V	V	K	435
1306	GCA	GCA	TCA	GTT	ATC	TGC	AGA	CTC	ATG	GAT	GAC	ATG	CAA	GGT	CAT	1350
436	A	A	S	V	I	C	R	L	M	D	D	M	Q	G	H	450
1351	GAG	TTT	GAG	CAG	AAG	AGA	GGA	CAT	GTT	GCG	TCA	GCT	ATT	GAA	TGT	1395
451	E	F	E	Q	K	R	G	H	V	A	S	A	I	E	C	465
1396	TAC	ACG	AAG	CAG	CAT	GGT	GTC	TCT	AAG	GAA	GAG	GCA	ATT	AAA	ATG	1440
466	Y	T	K	Q	H	G	V	S	K	E	E	A	I	K	M	480
1441	TTT	GAA	GAA	GAA	GTT	GCA	AAT	GCA	TGG	AAA	GAT	ATT	AAC	GAG	GAG	1485
481	F	E	E	E	V	A	N	A	W	K	D	I	N	E	E	495
1486	TTG	ATG	ATG	AAG	CCA	ACC	GTC	GTT	GCC	CGA	CCA	CTG	CTC	GGG	ACG	1530
496	L	M	M	K	P	T	V	V	A	R	P	L	L	G	T	510
1531	ATT	CTT	AAT	CTT	GCT	CGT	GCA	ATT	GAT	TTT	ATT	TAC	AAA	GAG	GAC	1575
511	I	L	N	L	A	R	A	I	D	F	I	Y	K	E	D	525
1576	GAC	GGC	TAT	ACG	CAT	TCT	TAC	CTA	ATT	AAA	GAT	CAA	ATT	GCT	TCT	1620
526	D	G	Y	T	H	S	Y	L	I	K	D	Q	I	A	S	540
1621	GTG	CTA	GGA	GAC	CAC	GTT	CCA	TTT	TGA							1647
541	V	L	G	D	H	V	P	F	*							

FIG. 8(e)-2

20/21

GFTpsE

1	ATG	TCT	TTG	GAA	GTT	TCA	GCC	TCT	CCT	GCT	AAA	GTT	ATC	CAA	AAT	45
1	M	S	L	E	V	S	A	S	P	A	K	V	I	Q	N	15
46	GCT	GGG	AAA	GAT	TCT	ACT	CGT	CGC	TCT	GCA	AAT	TAT	CAT	CCA	AGC	90
16	A	G	K	D	S	T	R	R	S	A	N	Y	H	P	S	30
91	ATC	TGG	GGG	GAT	CAT	TTC	CTT	CAA	TAT	ACT	TGT	GAC	ACC	CAG	GAA	135
31	I	W	G	D	H	F	L	Q	Y	T	C	D	T	Q	E	45
136	ACT	GAT	GAT	GGC	AGC	AAT	GTA	AAG	CAT	CTA	GAG	CTG	AAG	AAA	GAA	180
46	T	D	D	G	S	N	V	K	H	L	E	L	K	K	E	60
181	ATT	AGA	AGA	ATG	CTA	AAA	GCT	GAT	AAC	AAG	CCT	TCA	CGT	ACA	CTT	225
61	I	R	R	M	L	K	A	D	N	K	P	S	R	T	L	75
226	CAA	TTG	ATT	GAT	GCA	ATT	CAG	CGT	TTA	GGA	GTG	TCT	TAC	CAT	TTT	270
76	Q	L	I	D	A	I	Q	R	L	G	V	S	Y	H	F	90
271	GAA	AGT	GAG	ATT	GAT	GAA	ATA	TTG	GGA	AAG	ATG	CAT	AAG	GCT	TCC	315
91	E	S	E	I	D	E	I	L	G	K	M	H	K	A	S	105
316	CAA	GAC	TCT	GAT	CTT	TGT	GAT	AAT	GAA	AAT	GAT	GAG	CTC	TAT	TAT	360
106	Q	D	S	D	L	C	D	N	E	N	D	E	L	Y	Y	120
361	ATC	TCT	CTT	CAT	TTT	CGA	TTA	CTT	AGA	CAA	AAT	GGC	TAT	AAA	ATT	405
121	I	S	L	H	F	R	L	L	R	Q	N	G	Y	K	I	135
406	TCC	GCT	GAT	GTG	TTC	AAA	AAG	TTC	AAA	GAC	ACG	GAT	GGG	AAC	TTT	450
136	S	A	D	V	F	K	K	F	K	D	T	D	G	N	F	150
451	AAA	ACA	TCT	CTT	GCG	AAA	GAT	GTT	CGA	GGA	ATG	TTA	AGC	TTG	TAT	495
151	K	T	S	L	A	K	D	V	R	G	M	L	S	L	Y	165
496	GAA	GCT	ACG	CAT	CTC	GGG	GTA	CAT	GAA	GAA	GAT	ATA	CTA	GAT	GAA	540
166	E	A	T	H	L	G	V	H	E	E	D	I	L	D	E	180
541	GCG	CTT	GCT	TTC	ACC	ACT	AGT	CAC	CTA	GAG	TCA	ATA	GCG	ACT	CAT	585
181	A	L	A	F	T	T	S	H	L	E	S	I	A	T	H	195
586	CAA	ATC	AGG	TCT	CCA	CTT	GTT	GAA	CAA	GTC	AAA	CAT	GCC	TTA	GTT	630
196	Q	I	R	S	P	L	V	E	Q	V	K	H	A	L	V	210
631	CAG	CCT	ATC	CAC	AGG	GGC	TTC	CAA	AGG	CTT	GAG	GCA	AGA	CAG	TAC	675
211	Q	P	I	H	R	G	F	Q	R	L	E	A	R	Q	Y	225
676	ATT	CCT	ATC	TAT	CAA	GAA	GAA	TCT	CCC	CAC	AAT	GAA	GCT	CTG	TTA	720
226	I	P	I	Y	Q	E	E	S	P	H	N	E	A	L	L	240
721	ACT	TTT	GCA	AAG	TTA	GAT	TTT	AAC	AAA	TTG	CAA	AAG	CCT	CAC	CAG	765
241	T	F	A	K	L	D	F	N	K	L	Q	K	P	H	Q	255
766	AAG	GAA	CTC	GGT	GAT	ATT	TCA	AGG	TGG	TGG	AAA	GAA	TTA	GAC	TTT	810
256	K	E	L	G	D	I	S	R	W	W	K	E	L	D	F	270

FIG. 8(f)-1

21/21

811	GCA CAT AAG CTA CCT TTC ATA AGA GAT AGA GTT GCG GAG TGC TAC	855
271	A H K L P F I R D R V A E C Y	285
856	TTT TGG ATA TTA GGA GTG TAT TTC GAG CCC CAA TAT TCA TTT GCA	900
286	F W I L G V Y F E P Q Y S F A	300
901	AGA AGA ATA TTG ACG AAA GTG ATC TCC ATG ACT TCT GTT ATT GAT	945
301	R R I L T K V I S M T S V I D	315
946	GAT ATC TAT GAT GTG TAT GGC AAA ATT GAA GAA CTT GAG CTT TTT	990
316	D I Y D V Y G K I E E L E L F	330
991	ACT TCA GCT ATT GAG AGG TGG GAT ATC AGT GCC ATA GAT CAA CTT	1035
331	T S A I E R W D I S A I D Q L	345
1036	CCT GAG TAT ATG AAA TTG TGT TAT AGG GCC CTT CTT GAT GTT TTT	1080
346	P E Y M K L C Y R A L L D V F	360
1081	AGT GAA GCA GAG AAG GAT TTG GCC CCC CAA GGA AAA TCA TAC CGC	1125
361	S E A E K D L A P Q G K S Y R	375
1126	CTC TAT TAT GCA AAA GAA GCG ATG AAG AAT ATG GTT AAG AAT TAC	1170
376	L Y Y A K E A M K N M V K N Y	390
1171	TTC TAC GAA GCT AAA TGG TGT CTT CAG AAT TAT GTA CCT ACA GTG	1215
391	F Y E A K W C L Q N Y V P T V	405
1216	GAT GAG TAC ATG ACG GTT GCA TTA GTT ACA TCT GGC TCC CCA ATG	1260
406	D E Y M T V A L V T S G S P M	420
1261	TTG TCA ACC ACA TCC TTT GTT GGC ATG GGA GAC ATT GTA ACT AAA	1305
421	L S T T S F V G M G D I V T K	435
1306	GAA TCT TTT GAG TGG TTA TTC AGC AAT CCT AGA TTT ATT AGG GCT	1350
436	E S F E W L F S N P R F I R A	450
1351	TCT TCT ATA GTT TGC CGA CTC ATG GAT GAC ATA GTG TCA CAC AAG	1395
451	S S I V C R L M D D I V S H K	465
1396	TTT GAA CAA AGC AGA GGG CAC GTT GCC TCA AGC GTT GAG TGT TAC	1440
466	F E Q S R G H V A S S V E C Y	480
1441	ATG AAA CAA CAT GGA GCA ACA GAA GAG GAA GCA TGC AAT GAG TTT	1485
481	M K Q H G A T E E E A C N E F	495
1486	CGG AAA CAA GTT TCA AAT GCC TGG AAG GAT ATA AAT GAG GAC TGC	1530
496	R K Q V S N A W K D I N E D C	510
1531	CTA CGC CCA ACG GTT GTG CCA ATG CCA CTT CTG ATG CGA ATT CTC	1575
511	L R P T V V P M P L L M R I L	525
1576	AAT CTT ACA CGC GTT ATA GAT GTC ATT TAC AAG TAT GAA GAT GGC	1620
526	N L T R V I D V I Y K Y E D G	540
1621	TAC ACT CAT TCC GCA GTT GTG CTG AAA GAT TTT GTT GCT TCT TTG	1665
541	Y T H S A V V L K D F V A S L	555
1666	TTT ATT AAT CCT GTG CCG ATA TGA	1689
556	F I N P V P I *	

FIG. 8(f)-2